Celgene (CELG) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document and Entity Information
Entity Registrant Name	CELGENE CORP /DE/
Entity Central Index Key	816,284
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		785,654,567

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Net product sales	$ 2,312.6	$ 1,956.8	$ 6,621.9	$ 5,508.9
Other revenue	21.5	25.4	70.8	76
Total revenue	2,334.1	1,982.2	6,692.7	5,584.9
Expenses:
Cost of goods sold (excluding amortization of acquired intangible assets)	109.9	97.7	314.7	282.7
Research and development	1,304.5	675.1	2,920.5	1,845.7
Selling, general and administrative	550.3	497.6	1,696.3	1,483.5
Amortization of acquired intangible assets	63.6	63.7	190.9	194.7
Acquisition related charges and restructuring, net	226.2	1.5	215.9	11
Total costs and expenses	2,254.5	1,335.6	5,338.3	3,817.6
Operating income	79.6	646.6	1,354.4	1,767.3
Other income and (expense):
Interest and investment income, net	8.6	6.9	26.4	20.6
Interest (expense)	(88.5)	(53.5)	(186)	(124.4)
Other income (expense), net	(19.6)	(22.5)	83.2	(46.9)
Income (loss) before income taxes	(19.9)	577.5	1,278	1,616.6
Income tax provision	14.2	69	237	230.6
Net income (loss)	$ (34.1)	$ 508.5	$ 1,041	$ 1,386
Net income (loss) per common share:
Basic (in dollars per share)	$ (0.04)	$ 0.64	$ 1.31	$ 1.72
Diluted (in dollars per share)	$ (0.04)	$ 0.61	$ 1.26	$ 1.66
Weighted average shares:
Basic (in shares)	791.1	799.6	794.3	803.5
Diluted (in shares)	791.1	832.8	827.7	836.4

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ (34.1)	$ 508.5	$ 1,041	$ 1,386
Foreign currency translation adjustments	(4.2)	(36.6)	(11.9)	(32.5)
Pension liability adjustment	0	0	(7.6)	0
Net unrealized gains (losses) related to cash flow hedges:
Unrealized holding gains (losses)	(67.1)	382.8	277	342.5
Tax benefit	29.9	0	8.3	12.6
Unrealized gains (losses), net of tax expense (benefit) of [$x.x] and ($0.2) for the three months ended September 30, 2014, and 2013, respectively, and [$x.x] and $0 for the nine months ended September 30, 2014, and 2013, respectively.	37.2	(382.8)	(285.3)	(355.1)
Reclassification adjustment for (gains) losses included in net income	(91.4)	(0.1)	(249.6)	4.8
Tax (benefit)	(0.5)	(0.5)	(1.5)	(1.2)
Reclassification adjustment for (gains) losses included in net income, net of tax (expense) benefit of [$x.x] and $0.3 for the three months ended September 30, 2014 and 2013, respectively, and [$x.x] and $6.5 for the nine months ended September 30, 2014 and 2013, respectively.	(91.9)	(0.6)	(251.1)	3.6
Net unrealized gains (losses) on marketable securities available for sale:
Unrealized holding gains (losses)	(426.3)	64.6	(434.6)	196.9
Tax (expense) benefit	133.7	(22.2)	136.8	(67.3)
Unrealized gains (losses), net of tax expense (benefit) of [$x.x] and $58.5 for the three months ended September 30, 2014 and 2013, respectively, and [$x.x] and $78.4 for the nine months ended September 30, 2014 and 2013, respectively.	(292.6)	42.4	(297.8)	129.6
Reclassification adjustment for losses included in net income	10.9	1.2	11.6	4.2
Tax (benefit)	(3.9)	(0.4)	(4.1)	(1.5)
Reclassification adjustment for losses included in net income, net of tax	7	0.8	7.5	2.7
Total other comprehensive income (loss)	(418.9)	388.8	(275.6)	458.5
Comprehensive income	$ (453)	$ 897.3	$ 765.4	$ 1,844.5

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 6,016.5	$ 4,121.6
Marketable securities available for sale	1,489.1	3,425.1
Accounts receivable, net of allowances of $31.5 and $32.1 at September 30, 2015 and December 31, 2014, respectively	1,272.4	1,166.7
Inventory	420.9	393.1
Deferred income taxes	249.6	11.7
Other current assets	703.9	594.4
Total current assets	10,152.4	9,712.6
Property, plant and equipment, net	702	642.6
Intangible assets, net	10,715.8	4,067.6
Goodwill	4,742	2,191.2
Other assets	1,057	726.1
Total assets	27,369.2	17,340.1
Current liabilities:
Short-term borrowings and current portion of long-term debt	1,199.7	605.9
Accounts payable	189.4	198.2
Accrued expenses	1,504.8	991.1
Income taxes payable	5.9	12.7
Current portion of deferred revenue	74.8	28.5
Other current liabilities	169.3	275.8
Total current liabilities	3,143.9	2,112.2
Deferred revenue, net of current portion	29.4	27.8
Income taxes payable	322.8	272.9
Deferred income taxes	2,632.4	555.6
Other non-current liabilities	1,567.3	1,581.1
Long-term debt, net of discount	14,297.9	6,265.7
Total liabilities	$ 21,993.7	$ 10,815.3
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Preferred stock, $.01 par value per share, 5.0 million shares authorized; none outstanding at September 30, 2015 and December 31, 2014, respectively	$ 0	$ 0
Common stock, $.01 par value per share, 1,150.0 million shares authorized; issued 936.8 million and 924.8 million shares at September 30, 2015 and December 31, 2014, respectively	9.4	9.2
Common stock in treasury, at cost; 149.6 million and 124.6 million shares at September 30, 2015 and December 31, 2014, respectively	(13,613.4)	(10,698.8)
Additional paid-in capital	10,826.9	9,827.2
Retained earnings	7,513.4	6,472.4
Accumulated other comprehensive income	639.2	914.8
Total stockholders’ equity	5,375.5	6,524.8
Total liabilities and stockholders’ equity	$ 27,369.2	$ 17,340.1

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowances (in dollars)	$ 31.5	$ 32.1
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,150,000,000	1,150,000,000
Common stock, shares issued	936,800,000	924,800,000
Common stock, treasury	149,600,000	124,600,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 1,041	$ 1,386
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	86.6	78.1
Amortization	198.5	203.3
Deferred income taxes	(413.1)	(248.6)
Impairment charges	26.6	133.2
Change in value of contingent consideration	(17.2)	11
Net (gain) loss on sale of investments	(84.1)	4.2
Share-based compensation expense	426.4	319.2
Share-based employee benefit plan expense	24.1	29.3
Reclassification adjustment for cash flow hedges included in net income	(249.6)	4.8
Unrealized change in value of derivative instruments	209.8	(27.8)
Other, net	17.9	(3.5)
Change in current assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(145.8)	(46)
Inventory	(27.1)	(33.6)
Other operating assets	(17.6)	55.7
Accounts payable and other operating liabilities	256.2	74.3
Income tax payable	43.9	27.7
Payment of contingent consideration	0	(5)
Deferred revenue	49.3	11.4
Net cash provided by operating activities	1,425.8	1,973.7
Cash flows from investing activities:
Proceeds from sales of marketable securities available for sale	3,661.7	1,662.2
Purchases of marketable securities available for sale	(1,699.4)	(2,137)
Payments for acquisition of businesses, net of cash acquired	(7,579.3)	(710)
Capital expenditures	(145.5)	(100.9)
Purchases and sales of investment securities, net	(130.8)	(58.4)
Other investing activities	(4.5)	(21)
Net cash used in investing activities	(5,897.8)	(1,365.1)
Cash flows from financing activities:
Payment for treasury shares	(2,574.1)	(2,433.8)
Proceeds from short-term borrowing	2,230.9	2,436.9
Principal repayments on short-term borrowing	(1,630.8)	(2,881.9)
Proceeds from issuance of long-term debt	7,913.3	2,470.6
Proceeds from sale of common equity put options	10.2	5.8
Payment of contingent consideration	0	(15)
Net proceeds from share-based compensation arrangements	204.2	205.1
Excess tax benefit from share-based compensation arrangements	243.7	146.4
Net cash provided by (used in) financing activities	6,397.4	(65.9)
Effect of currency rate changes on cash and cash equivalents	(30.5)	(34.6)
Net increase (decrease) in cash and cash equivalents	1,894.9	508.1
Cash and cash equivalents at beginning of period	4,121.6	3,234.4
Cash and cash equivalents at end of period	6,016.5	3,742.5
Supplemental schedule of non-cash investing and financing activity:
Fair value of contingent consideration issued in business combinations	0	1,060
Change in net unrealized (gain) loss on marketable securities available for sale	434.6	(196.9)
Investment in NantBioScience, Inc. preferred equity	0	90
Supplemental disclosure of cash flow information:
Interest paid	171.1	126.2
Income taxes paid	$ 345.6	$ 275

Nature of Business and Basis of

Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation Celgene Corporation, together with its subsidiaries (collectively “we,” “our,” “us,” “Celgene” or the “Company”), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. We are dedicated to innovative research and development designed to bring new therapies to market and we are involved in research in several scientific areas designed to deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. Our primary commercial stage products include REVLIMID ® , ABRAXANE ® , POMALYST ® /IMNOVID ® , VIDAZA ® , azacitidine for injection (generic version of VIDAZA ® ), THALOMID ® (sold as THALOMID ® or Thalidomide Celgene TM outside of the U.S.), OTEZLA ® and ISTODAX ® . OTEZLA ® was approved by the U.S. Food and Drug Administration (FDA) in March 2014 for the treatment of adult patients with active psoriatic arthritis and in September 2014 for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In January 2015, OTEZLA ® was approved by the European Commission (EC) for the treatment of both psoriasis and psoriatic arthritis in certain adult patients. We began recognizing revenue related to OTEZLA ® during the second quarter of 2014. Additional sources of revenue include royalties from Novartis Pharma AG (Novartis) on their sales of FOCALIN XR ® and the entire RITALIN ® family of drugs, the sale of products and services through our Celgene Cellular Therapeutics (CCT) subsidiary and other licensing arrangements. The consolidated financial statements include the accounts of Celgene Corporation and its subsidiaries. Investments in limited partnerships and interests where we have an equity interest of 50% or less and do not otherwise have a controlling financial interest are accounted for by either the equity or cost method. Certain prior year amounts have been reclassified to conform to the current year's presentation. The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. We are subject to certain risks and uncertainties related to, among other things, product development, regulatory approval, market acceptance, scope of patent and proprietary rights, competition, outcome of legal and governmental proceedings, European credit risk, technological change and product liability. Interim results may not be indicative of the results that may be expected for the full year. In the opinion of management, these unaudited consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim unaudited consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Our significant accounting policies are described in Note 1 of Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 (2014 Annual Report on Form 10-K). New Accounting Pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2018 using one of two prescribed transition methods. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (ASU 2015-03). ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable IFRS standards by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, similar to the presentation of debt discounts or premiums. This accounting guidance is effective for us beginning in the first quarter of 2016. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures. In April 2015, the FASB issued Accounting Standards Update No. 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement" (ASU 2015-05). ASU 2015-05 provides guidance to help companies evaluate the accounting for fees paid by a customer in a cloud computing arrangement. The new guidance clarifies that if a cloud computing arrangement includes a software license, the customer should account for the license consistent with its accounting for other software licenses. If the arrangement does not include a software license, the customer should account for the arrangement as a service contract. ASU 2015-05 is effective for us beginning in the first quarter of 2016. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In July 2015, the FASB issued Accounting Standards Update No. 2015-11, "Inventory (Topic 330): Simplifying the Measurement of Inventory" (ASU 2015-11). ASU 2015-11 applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In August 2015, the FASB issued Accounting Standards Update No. 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" (ASU 2015-15). ASU 2015-15 clarifies the presentation and subsequent measurement of debt issuance costs associated with lines of credit. These costs may be presented as an asset and amortized ratably over the term of the line of credit arrangement, regardless of whether there are outstanding borrowings on the arrangement. The effective date will be the first quarter of fiscal year 2017 and will be applied retrospectively. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures. In September 2015, the FASB issued Accounting Standards Update No. 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments" (ASU 2015-16). ASU 2015-16 replaces the requirement that an acquirer in a business combination account for measurement period adjustments retrospectively with a requirement that an acquirer recognize adjustments to the provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. ASU 2015-16 requires that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. ASU 2015-16 will be effective is effective for us beginning in the first quarter of 2016. The guidance is to be applied prospectively to adjustments to provisional amounts that occur after the effective date of the guidance, with earlier application permitted for financial statements that have not been issued. We do not expect the adoption of this updated standard to have a material impact on our consolidated financial statements and related disclosures.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisition	Acquisitions Receptos, Inc. (Receptos): On August 27, 2015 (Acquisition Date), we acquired all of the outstanding common stock of Receptos, resulting in Receptos becoming our wholly-owned subsidiary. Receptos' lead drug candidate, ozanimod, is a small molecule that modulates sphingosine 1-phosphate 1 and 5 receptors and it is in development for immune-inflammatory indications, including inflammatory bowel disease and relapsing multiple sclerosis (RMS). In clinical trial results, ozanimod demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and RMS, including its cardiac, hepatotoxicity and lymphocyte recovery profile. The phase III TRUE NORTH trial in UC is currently underway with data expected in 2018. The phase III RADIANCE and SUNBEAM RMS trials are ongoing and data are expected in the first half of 2017. Receptos is also developing RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), which has been designated as an orphan disease. RPC4046 was licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (collectively referred to as AbbVie) and is currently in phase II testing for EoE. The results of operations for Receptos are included in our consolidated financial statements from the Acquisition Date and the assets and liabilities of Receptos have been recorded at their respective fair values on the Acquisition Date and consolidated with our assets and liabilities. We paid approximately $7.626 billion , consisting of $7.311 billion for common stock outstanding and $0.315 billion for the portion of equity compensation attributable to the pre-combination period. In addition, we will pay $0.197 billion for the portion of equity compensation attributable to the post-combination service period, which will be recorded as expense over the required service period ending in the fourth quarter of 2015. The acquisition has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and requires the fair value of acquired in-process research and development (IPR&D) to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. A preliminary purchase price allocation has been performed and the recorded amounts for intangible assets, goodwill and associated deferred tax assets and liabilities are subject to change pending finalization of valuation efforts. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. The total consideration for the acquisition of Receptos was $7,626.2 million , consisting of cash and is summarized as follows: Total Consideration Cash paid for outstanding common stock $ 7,311.3 Cash for equity compensation attributable to pre-combination service (1) 314.9 Total consideration $ 7,626.2 (1) $28.6 million for equity compensation attributable to pre-combination service remained payable at September 30, 2015 and will be paid prior to December 31, 2015. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below: Amounts Recognized as of the Acquisition Date (Provisional) Working capital (1) $ 479.2 Current deferred tax assets 238.2 Property, plant and equipment 5.0 In-process research and development product rights 6,842.0 Other non-current assets 7.9 Non-current deferred tax liabilities (2,497.0 ) Total identifiable net assets 5,075.3 Goodwill 2,550.9 Total net assets acquired $ 7,626.2 (1) Includes cash and cash equivalents, available for sale marketable securities, other current assets, accounts payable and other current liabilities. The fair values of current assets, current liabilities and property, plant and equipment were determined to approximate their book values. The fair value assigned to acquired IPR&D was based on the present value of expected after-tax cash flows attributable to ozanimod, which is in phase II and III testing. The present value of expected after-tax cash flows attributable to ozanimod and assigned to IPR&D was determined by estimating the after-tax costs to complete development of ozanimod into a commercially viable product, estimating future revenue and ongoing expenses to produce, support and sell ozanimod, on an after-tax basis, and discounting the resulting net cash flows to present value. The revenue and costs projections used were reduced based on the probability that compounds at similar stages of development will become commercially viable products. The rate utilized to discount the net cash flows to their present value reflects the risk associated with the intangible asset and is benchmarked to the cost of equity. Acquired IPR&D will be accounted for as an indefinite-lived intangible asset until regulatory approval in a major market or discontinuation of development. The excess of purchase price over the fair value amounts assigned to identifiable assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is primarily attributable to the broadening of our product portfolio and research capabilities in the inflammation and immunology therapeutic area and the assembled workforce. We do not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the acquisition has been recorded as a non-current asset in our Consolidated Balance Sheets and is not amortized, but is subject to review for impairment annually. As a result of the exclusive development license from AbbVie for RPC4046 that Receptos held prior to our acquisition of Receptos, AbbVie holds an option to enter into a global collaboration for RPC4046 with us following the availability of results from the current phase II study. If AbbVie does not exercise its option, we will have an exclusive worldwide license for the development and commercialization of RPC4046 that will be unlimited as to indications. We do not consider this potential collaboration arrangement to be significant. From the Acquisition Date through September 30, 2015, our Consolidated Statements of Operations included expenses of $235.3 million associated with the acquisition and operations of Receptos as follows (1) : Statements of Operations Location Acquisition Date Through September 30, 2015 Research and development $ 21.9 Selling, general and administrative 1.1 Acquisition related (gains) charges and restructuring, net (2) 211.7 Other income (expense), net 0.6 Total $ 235.3 (1) In addition, Celgene incurred $19.9 million of acquisition related costs prior to the acquisition date. (2) Consists of acquisition-related compensation expense and transaction costs. Pro Forma Financial Information: The following table provides unaudited pro forma financial information for the three- and nine-month periods ended September 30, 2015 and 2014 as if the acquisition of Receptos had occurred on January 1, 2014. Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Total revenue $ 2,334.1 $ 1,985.7 $ 6,692.7 $ 5,590.8 Net income $ 107.3 $ 445.4 $ 1,029.8 $ 952.2 Net income per common share: basic $ 0.14 $ 0.56 $ 1.30 $ 1.19 Net income per common share: diluted $ 0.13 $ 0.53 $ 1.24 $ 1.14 The unaudited pro forma financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Celgene and Receptos. The pro-forma financial information assumes that the acquisition-related transaction fees and costs incurred were removed from the three-month period ended September 30, 2015 and were assumed to have been incurred during the first quarter of 2014. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the combined operations of Celgene and Receptos. Accordingly, these unaudited pro forma results are presented for illustrative purposes and are not intended to represent or be indicative of the actual results of operations of the combined company that would have been achieved had the acquisition occurred at the beginning of the period presented, nor are they intended to represent or be indicative of future results of operations. Quanticel Pharmaceuticals, Inc. (Quanticel): On October 19, 2015, we completed our previously announced acquisition of Quanticel, a privately held biotechnology company focused on cancer drug discovery, for consideration consisting of $100.0 million in cash at closing plus contingent consideration consisting of future payments of up to $385.0 million for achieving specified discovery and development targets. We have had a research collaboration arrangement with Quanticel since 2011. Through this purchase, Quanticel has become our wholly-owned subsidiary, and we will benefit from full access to Quanticel’s proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticel’s programs that target specific epigenetic modifiers, which we expect will advance our pipeline of innovative cancer therapies. The acquisition will be accounted for using the acquisition method of accounting for business combinations which requires the assets and liabilities of Quanticel to be recorded at their respective fair values on the acquisition date and consolidated into our Consolidated Balance Sheets. The results of operations for Quanticel will be included in our consolidated financial statements from the date of acquisition. Due to the limitations on access to Quanticel information prior to the acquisition date and the limited time since the acquisition date, the initial accounting for the business combination is incomplete at this time. As a result, we are unable to provide contingent consideration disclosures and the amounts recognized as of the acquisition date for the major classes of assets acquired and liabilities assumed, including the information required for net working capital, pre-acquisition contingencies, intangible assets and goodwill. This information will be included in our 2015 Annual Report on Form 10-K. Nogra Pharma Limited (Nogra): On April 23, 2014, we entered into a license agreement with Nogra, pursuant to which Nogra granted us an exclusive, royalty-bearing license in its intellectual property relating to GED-0301, an antisense oligonucleotide targeting Smad7, to develop and commercialize products containing GED-0301 for the treatment of Crohn’s disease and other indications. Based on our evaluation of the license agreement, our level of control and decision making authority over the development and application of the intellectual property, the associated transfer of manufacturing agreements and knowhow, and access to employees of Nogra, we concluded that the acquired assets met the definition of a business and we have accounted for the GED-0301 license as IPR&D acquired in a business combination. The assets acquired and liabilities assumed of Nogra were recorded on our balance sheet as of May 14, 2014 (Effective Date), at their respective fair values. Nogra's results of operations are included in our consolidated financial statements from the Effective Date. We made an upfront payment of $710.0 million and may make additional contingent developmental, regulatory and sales milestone payments as well as payments based on percentages of annual sales of licensed products. The maximum aggregate amount payable for development and regulatory milestones is approximately $815.0 million , which covers such milestones relating to Crohn’s disease and other indications. Starting from global annual net sales of $500.0 million , aggregate tiered sales milestone payments could total a maximum of $1.050 billion if global annual net sales reach $4.000 billion . Subsequent to the Effective Date, we have measured the contingent consideration at fair value each period with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the IPR&D assets and the passage of time. At September 30, 2015, the balance of the contingent consideration was $1.213 billion , of which $25.0 million is included in other current liabilities and $1.188 billion included in other non-current liabilities.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, (Amounts in millions, except per share) 2015 2014 2015 2014 Net income (loss) $ (34.1 ) $ 508.5 $ 1,041.0 $ 1,386.0 Weighted-average shares: Basic 791.1 799.6 794.3 803.5 Effect of dilutive securities: Options, restricted stock units and other incentives — 33.2 33.4 32.9 Diluted 791.1 832.8 827.7 836.4 Net income (loss) per share: Basic $ (0.04 ) $ 0.64 $ 1.31 $ 1.72 Diluted $ (0.04 ) $ 0.61 $ 1.26 $ 1.66 The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 32.5 million and 13.7 million for the three-month periods ended September 30, 2015 and 2014 , respectively. The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 11.6 million and 17.9 million shares for the nine-month periods ended September 30, 2015 and 2014 , respectively. All of the potentially dilutive securities for the three-month period ended September 30, 2015 were determined to be anti-dilutive due to the net loss reported. Share Repurchase Program: In June 2015, our Board of Directors approved an increase of $4.000 billion to our authorized share repurchase program, bringing the total amount authorized since April 2009 to an aggregate of up to $17.500 billion of our common stock. As part of the management of our share repurchase program, we may, from time to time, sell put options on our common stock with strike prices that we believe represent an attractive price to purchase our shares. If the trading price of our shares exceeds the strike price of the put option at the time the option expires, we will have economically reduced the cost of our share repurchase program by the amount of the premium we received from the sale of the put option. If the trading price of our stock is below the strike price of the put option at the time the option expires, we would purchase the shares covered by the option at the strike price of the put option. During the three-month and nine-month periods ended September 30, 2015 and 2014, we recorded losses and gains from put option activity on our Consolidated Statements of Operations in other income (expense), net as follows: Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Gain (loss) from sale of put options $ (18.8 ) $ 3.6 $ (9.9 ) $ 9.9 At September 30, 2015 , we had no outstanding put options. We have purchased 7.1 million and 24.5 million shares of common stock under the share repurchase program from all sources at a total cost of $815.4 million and $2.849 billion during the three- and nine-month periods ended September 30, 2015 , respectively. As of September 30, 2015 , we had a remaining share repurchase authorization of $4.297 billion .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) The components of other comprehensive income (loss) consist of changes in pension liability, changes in net unrealized gains (losses) on marketable securities classified as available-for-sale, net unrealized gains (losses) related to cash flow hedges and changes in foreign currency translation adjustments. The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Pension Liability Net Unrealized Gains (Losses) From Marketable Securities Net Unrealized Gains (Losses) From Hedges Foreign Currency Translation Adjustment Total Accumulated Other Comprehensive Income (Loss) Balance December 31, 2014 $ (15.5 ) $ 460.9 $ 519.6 $ (50.2 ) $ 914.8 Other comprehensive income (loss) before reclassifications (7.6 ) (297.8 ) 285.3 (11.9 ) (32.0 ) Amounts reclassified from accumulated other comprehensive income — 7.5 (251.1 ) — (243.6 ) Net current-period other comprehensive income (loss) (7.6 ) (290.3 ) 34.2 (11.9 ) (275.6 ) Balance September 30, 2015 $ (23.1 ) $ 170.6 $ 553.8 $ (62.1 ) $ 639.2 Balance December 31, 2013 $ (6.9 ) $ 137.3 $ (36.0 ) $ (0.4 ) $ 94.0 Other comprehensive income (loss) before reclassifications — 129.6 355.1 (32.5 ) 452.2 Amounts reclassified from accumulated other comprehensive income — 2.7 3.6 — 6.3 Net current-period other comprehensive income (loss) — 132.3 358.7 (32.5 ) 458.5 Balance September 30, 2014 $ (6.9 ) $ 269.6 $ 322.7 $ (32.9 ) $ 552.5 Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income Components Affected Line Item in the Consolidated Statements of Operations Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Gains (losses) from cash-flow hedges: Foreign exchange contracts Net product sales $ 92.9 $ 1.3 $ 253.6 $ (1.7 ) Treasury rate lock agreements Interest (expense) (1.1 ) (0.9 ) (2.9 ) (2.6 ) Interest rate swap agreements Interest (expense) (0.4 ) (0.3 ) (1.1 ) (0.5 ) Income tax benefit 0.5 0.5 1.5 1.2 Gains (losses) from available-for-sale marketable securities: Realized income (loss) on sales of marketable securities Interest and investment income, net (10.9 ) (1.2 ) (11.6 ) (4.2 ) Income tax benefit 3.9 0.4 4.1 1.5 Total reclassification, net of tax $ 84.9 $ (0.2 ) $ 243.6 $ (6.3 )

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurement	Financial Instruments and Fair Value Measurement The table below presents information about assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2015 and the valuation techniques we utilized to determine such fair value. • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Our Level 1 assets consist of marketable equity securities. Our Level 1 liability relates to our publicly traded Contingent Value Rights (CVRs). See Note 18 of Notes to Consolidated Financial Statements included in our 2014 Annual Report on Form 10-K for a description of the CVRs. • Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Our Level 2 assets consist primarily of U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency MBS, non-U.S. government, agency and supranational securities, global corporate debt securities, asset backed securities, foreign currency forward contracts, purchased foreign currency options and interest rate swap contracts. Our Level 2 liabilities relate to written foreign currency options, foreign currency forward contracts and interest rate swap contracts. • Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. We do not have any Level 3 assets. Our Level 3 liabilities consist of contingent consideration related to undeveloped product rights resulting from the acquisitions of Gloucester Pharmaceuticals, Inc. (Gloucester) and Nogra in addition to contingent consideration related to the undeveloped product rights and technology platform acquired as part of the acquisition of Avila Therapeutics, Inc. (now known as Celgene Avilomics Research, Inc.) (Avila). The maximum remaining potential payments related to the contingent consideration from the acquisitions of Gloucester and Avila are estimated to be $120.0 million and $555.0 million , respectively, and $1.865 billion plus amounts based on sales pursuant to the license agreement with Nogra. Balance at September 30, 2015 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 1,489.1 $ 1,111.3 $ 377.8 $ — Forward currency contracts 599.9 — 599.9 — Purchased currency options 36.3 — 36.3 — Interest rate swaps 89.8 — 89.8 — Total assets $ 2,215.1 $ 1,111.3 $ 1,103.8 $ — Liabilities: Contingent value rights $ (69.7 ) $ (69.7 ) $ — $ — Written currency options (18.7 ) — (18.7 ) — Other acquisition related contingent consideration (1,328.5 ) — — (1,328.5 ) Total liabilities $ (1,416.9 ) $ (69.7 ) $ (18.7 ) $ (1,328.5 ) Balance at December 31, 2014 Quoted Price in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Available-for-sale securities $ 3,425.1 $ 1,051.3 $ 2,373.8 $ — Forward currency contracts 550.7 — 550.7 — Purchased currency options 9.8 — 9.8 — Interest rate swaps 20.0 — 20.0 — Total assets $ 4,005.6 $ 1,051.3 $ 2,954.3 $ — Liabilities: Contingent value rights $ (136.3 ) $ (136.3 ) $ — $ — Written currency options (4.6 ) — (4.6 ) — Other acquisition related contingent consideration (1,279.0 ) — — (1,279.0 ) Total liabilities $ (1,419.9 ) $ (136.3 ) $ (4.6 ) $ (1,279.0 ) There were no security transfers between Levels 1 and 2 during the nine-month periods ended September 30, 2015 and 2014 . The following table represents a roll-forward of the fair value of Level 3 instruments: Nine-Month Periods Ended September 30, 2015 2014 Liabilities: Balance at beginning of period $ (1,279.0 ) $ (228.5 ) Amounts acquired or issued — (1,060.0 ) Net change in fair value (49.5 ) 17.6 Settlements — 20.0 Transfers in and/or out of Level 3 — — Balance at end of period $ (1,328.5 ) $ (1,250.9 ) Level 3 liabilities outstanding as of September 30, 2015 primarily consisted of contingent consideration related to the acquisitions of Avila and Nogra. The $49.5 million net increase in the fair value of Level 3 liabilities in 2015 was related to accretion of the fair value of our contingent consideration due to the passage of time, which was partly offset by reductions in the probability and delays in the assumed timing of certain contingent consideration milestones related to the acquisition of Avila. Changes to the fair value of contingent consideration are recorded on the Consolidated Statements of Operations as acquisition related charges and restructuring, net.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities Our revenue and earnings, cash flows and fair values of assets and liabilities can be impacted by fluctuations in foreign exchange rates and interest rates. We actively manage the impact of foreign exchange rate and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency option contracts, foreign currency forward contracts, treasury rate lock agreements and interest rate swap contracts. In instances where these financial instruments are accounted for as cash flow hedges or fair value hedges we may from time to time terminate the hedging relationship. If a hedging relationship is terminated we generally either settle the instrument or enter into an offsetting instrument. Foreign Currency Risk Management We maintain a foreign exchange exposure management program to mitigate the impact of volatility in foreign exchange rates on future foreign currency cash flows, translation of foreign earnings and changes in the fair value of assets and liabilities denominated in foreign currencies. Through our revenue hedging program, we endeavor to reduce the impact of possible unfavorable changes in foreign exchange rates on our future U.S. dollar cash flows that are derived from foreign currency denominated sales. To achieve this objective, we hedge a portion of our forecasted foreign currency denominated sales that are expected to occur in the foreseeable future, typically within the next three years. We manage our anticipated transaction exposure principally with foreign currency forward contracts and occasionally foreign currency put and call options. Foreign Currency Forward Contracts: We use foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, manage exchange rate volatility in the translation of foreign earnings, and reduce exposures to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. We manage a portfolio of foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated revenues and expenses of foreign subsidiaries. The foreign currency forward hedging contracts outstanding at September 30, 2015 and December 31, 2014 had settlement dates within 36 months . The spot rate components of these foreign currency forward contracts are designated as cash flow hedges and, to the extent effective, any unrealized gains or losses are reported in other comprehensive income (OCI) and reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. If a hedging relationship is terminated with respect to a foreign currency forward contract, accumulated gains or losses associated with the contract remain in OCI until the hedged forecasted transaction occurs and are reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. Any ineffectiveness on these foreign currency forward contracts is reported on the Consolidated Statements of Operations in other income (expense), net. The forward point components of these foreign currency forward contracts are not designated as cash flow hedges and all fair value adjustments of forward point amounts are recorded to other income (expense), net. Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2015 and December 31, 2014 : Notional Amount Foreign Currency September 30, 2015 December 31, 2014 Australian Dollar $ 38.6 $ 18.8 British Pound 332.6 304.8 Canadian Dollar 84.4 43.7 Euro 3,290.3 3,375.7 Japanese Yen 555.2 541.1 Total $ 4,301.1 $ 4,284.1 We consider the impact of our own and the counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its obligations under the contract on an ongoing basis. As of September 30, 2015 , credit risk did not materially change the fair value of our foreign currency forward contracts. We also manage a portfolio of foreign currency contracts to reduce exposures to foreign currency fluctuations of certain recognized assets and liabilities denominated in foreign currencies and, from time to time, we enter into foreign currency contracts to manage exposure related to translation of foreign earnings. These foreign currency forward contracts have not been designated as hedges and, accordingly, any changes in their fair value are recognized on the Consolidated Statements of Operations in other income (expense), net in the current period. The aggregate notional amount of the foreign currency forward non-designated hedging contracts outstanding at September 30, 2015 and December 31, 2014 were $831.8 million and $835.5 million , respectively. Foreign Currency Option Contracts: From time to time, we may hedge a portion of our future foreign currency exposure by utilizing a strategy that involves both a purchased local currency put option and a written local currency call option that are accounted for as hedges of future sales denominated in that local currency. Specifically, we sell (or write) a local currency call option and purchase a local currency put option with the same expiration dates and local currency notional amounts but with different strike prices. This combination of transactions is generally referred to as a “collar.” The expiration dates and notional amounts correspond to the amount and timing of forecasted foreign currency sales. If the U.S. dollar weakens relative to the currency of the hedged anticipated sales, the purchased put option value reduces to zero and we benefit from the increase in the U.S. dollar equivalent value of our anticipated foreign currency cash flows; however, this benefit would be capped at the strike level of the written call, which forms the upper end of the collar. The premium collected from the sale of the call option is equal to the premium paid for the purchased put option, resulting in a net zero cost for each collar. Outstanding foreign currency option contracts entered into to hedge forecasted revenue were as follows at September 30, 2015 and December 31, 2014 : Notional Amount 1 September 30, 2015 December 31, 2014 Foreign currency option contracts designated as hedging activity: Purchased Put $ 524.1 $ 152.6 Written Call $ 562.4 $ 160.9 1 U.S. dollar notional amounts are calculated as the hedged local currency amount multiplied by the strike value of the foreign currency option. The local currency notional amounts of our purchased put and written call that are designated as hedging activities are equal to each other. Interest Rate Risk Management In anticipation of issuing fixed-rate debt, we may use forward starting interest rate swaps (forward starting swaps) or treasury rate lock agreements (treasury rate locks) that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. To the extent these hedges of cash flows related to anticipated debt are effective, any realized or unrealized gains or losses on the treasury rate locks or forward starting swaps are reported in OCI and are recognized in income over the life of the anticipated fixed-rate notes. Forward Starting Interest Rate Swaps and Treasury Rate Locks: In anticipation of issuing debt in 2015, we entered into forward starting swaps and treasury rate locks, that were designated as cash flow hedges, with aggregate notional value of $1.300 billion and $1.600 billion , respectively. All forward starting swaps and treasury rate locks were settled upon the issuance of debt in August 2015, when the net fair value of the forward starting swaps and treasury rate locks in accumulated other comprehensive income was in a loss position of $21.6 million . The net loss will be recognized as interest expense over the life of the associated senior notes. During October 2015, we entered into forward starting swaps with effective dates in September 2017 and maturing in ten years. Interest Rate Swap Contracts: From time to time we hedge the fair value of certain debt obligations through the use of interest rate swap contracts. The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in interest rates. Since the specific terms and notional amount of the swap are intended to match those of the debt being hedged, it is assumed to be a highly effective hedge and all changes in fair value of the swap are recorded on the Consolidated Balance Sheets with no net impact recorded in income. Any net interest payments made or received on interest rate swap contracts are recognized as interest expense. If a hedging relationship is terminated for an interest rate swap contract, accumulated gains or losses associated with the contract are measured and recorded as a reduction or increase of current and future interest expense associated with the previously hedged debt obligations. We have entered into swap contracts that were designated as hedges of certain of our fixed rate notes and also terminated the hedging relationship by settling certain of those swap contracts during 2014 and 2015. The settlement of swap contracts resulted in the receipt of net proceeds of $7.7 million and $15.3 million during the nine-month periods ended September 30, 2015 and 2014 , respectively, which are accounted for as a reduction of current and future interest expense associated with these notes. See Note 11 for additional details related to reductions of current and future interest expense. The following table summarizes the notional amounts of our outstanding swap contracts at September 30, 2015 and December 31, 2014 : Notional Amount September 30, 2015 December 31, 2014 Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes: 2.450% senior notes due 2015 $ 300.0 $ 300.0 1.900% senior notes due 2017 300.0 300.0 2.300% senior notes due 2018 200.0 200.0 2.250% senior notes due 2019 500.0 500.0 3.950% senior notes due 2020 500.0 500.0 3.250% senior notes due 2022 1,000.0 750.0 4.000% senior notes due 2023 700.0 150.0 3.625% senior notes due 2024 100.0 — Total $ 3,600.0 $ 2,700.0 The following tables summarize the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2015 and December 31, 2014 : September 30, 2015 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 329.5 $ 28.1 Other current liabilities 0.5 1.8 Other non-current assets 321.3 33.3 Interest rate swap agreements Other current assets 23.6 — Other non-current assets 65.1 — Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 39.4 9.1 Other current liabilities — 0.9 Interest rate swap agreements Other current assets 0.7 0.7 Other non-current assets 1.4 0.3 Total $ 781.5 $ 74.2 December 31, 2014 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts (1) Other current assets $ 264.9 $ 44.9 Other current liabilities 0.1 1.7 Other non-current assets 322.3 17.5 Interest rate swap agreements Other current assets 17.9 — Other non-current assets 4.8 0.3 Other non-current liabilities — 3.8 Derivatives not designated as hedging instruments: Foreign exchange contracts (1) Other current assets 39.7 6.0 Other current liabilities 0.1 1.1 Interest rate swap agreements Other current assets 0.1 — Other non-current assets 1.3 — Total $ 651.2 $ 75.3 (1) Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20. The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Operations for the three-month periods ended September 30, 2015 and 2014 : Three-Month Period Ended September 30, 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of (1) Location of Amount of Location of Amount of Foreign exchange contracts $ 10.8 Net product sales $ 92.9 Other income, net $ 14.8 (2 ) Treasury rate lock agreements $ (27.9 ) Interest expense $ (1.1 ) Other income, net $ (0.2 ) (3 ) Interest rate swap agreements $ (50.0 ) Interest expense $ (0.4 ) Other income, net $ 0.3 (3 ) (1) Net gains of $320.3 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. (2) The amount of net gains recognized in income represents $14.7 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $0.1 million in gains related to the ineffective portion of the hedging relationships. (3) The amount of net gain recognized in income relates to the ineffective portion of the hedging relationships. Three-Month Period Ended September 30, 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Location of Amount of Location of Amount of Foreign exchange contracts $ 382.8 Net product sales $ 1.3 Other income, net $ (16.4 ) (1 ) Treasury rate lock agreements $ — Interest expense $ (0.9 ) Other income, net $ — Interest rate swap agreements $ — Interest expense $ (0.3 ) Other income, net $ — (1) The amount of net losses recognized in income represents $18.6 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.2 million in gains related to the ineffective portion of the hedging relationships. The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Operations for the nine-month periods ended September 30, 2015 and 2014 : Nine-Month Period Ended September 30, 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of (1) Location of Amount of Location of Amount of Foreign exchange contracts $ 298.7 Net product sales $ 253.6 Other income, net $ 32.2 (2 ) Treasury rate lock agreements $ (27.9 ) Interest expense $ (2.9 ) Other income, net (0.2 ) (3 ) Interest rate swap agreements $ 6.2 Interest expense $ (1.1 ) Other income, net 0.3 (3 ) (1) Net gains of $320.3 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. (2) The amount of net gains recognized in income represents $35.5 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $3.3 million in losses related to the ineffective portion of the hedging relationships. (3) The amount of net gain recognized in income relates to the ineffective portion of the hedging relationships. Nine-Month Period Ended September 30, 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Location of Amount of Location of Amount of Foreign exchange contracts $ 374.9 Net product sales $ (1.7 ) Other income, net $ (19.2 ) (1 ) Treasury rate lock agreements $ — Interest expense $ (2.6 ) Other income, net $ — Interest rate swap agreements $ (32.4 ) Interest expense $ (0.5 ) Other income, net $ (3.6 ) (2 ) (1) The amount of net losses recognized in income represents $22.1 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.9 million in gains related to the ineffective portion of the hedging relationships. (2) The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships. The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain (Loss) Recognized in Income on Derivative Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, Instrument 2015 2014 2015 2014 Interest rate swap agreements Interest expense $ 16.2 $ 10.3 $ 45.5 $ 31.2 The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain (Loss) Recognized in Income on Derivative Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, Instrument 2015 2014 2015 2014 Foreign exchange contracts Other income (expense), net $ 14.4 $ 55.4 $ 69.3 $ 44.3 Put options on our common stock Other income (expense), net $ (18.8 ) $ 3.6 $ (9.9 ) $ 9.9 The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Operations in other income (expense), net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each Income Statement account in current and/or future periods.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities Available-for-Sale	9 Months Ended
	Sep. 30, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents and Marketable Securities Available-for-Sale	Cash, Cash Equivalents and Marketable Securities Available-for-Sale Money market funds of $2.101 billion and $2.251 billion at September 30, 2015 and December 31, 2014 , respectively, were recorded at cost, which approximates fair value and are included in cash and cash equivalents. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at September 30, 2015 and December 31, 2014 were as follows: September 30, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 92.8 $ — $ — $ 92.8 U.S. government-sponsored agency MBS 34.0 — (0.2 ) 33.8 Corporate debt - global 213.4 0.2 (1.0 ) 212.6 Asset backed securities 38.6 — — 38.6 Marketable equity securities 820.3 365.8 (74.8 ) 1,111.3 Total available-for-sale marketable securities $ 1,199.1 $ 366.0 $ (76.0 ) $ 1,489.1 December 31, 2014 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 1,044.7 $ 0.3 $ (0.8 ) $ 1,044.2 U.S. government-sponsored agency securities 145.1 0.1 (0.1 ) 145.1 U.S. government-sponsored agency MBS 531.1 1.0 (2.7 ) 529.4 Non-U.S. government, agency and Supranational securities 32.4 — (0.1 ) 32.3 Corporate debt - global 446.3 0.6 (1.2 ) 445.7 Asset backed securities 177.3 — (0.2 ) 177.1 Marketable equity securities 335.2 716.3 (0.2 ) 1,051.3 Total available-for-sale marketable securities $ 2,712.1 $ 718.3 $ (5.3 ) $ 3,425.1 U.S. government-sponsored agency securities include general unsecured obligations either issued directly by or guaranteed by U.S. Government Sponsored Enterprises. U.S. government-sponsored agency MBS include mortgage-backed securities issued by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association. Non-U.S. government, agency and supranational securities consist of direct obligations of highly rated governments of nations other than the United States and obligations of sponsored agencies and other entities that are guaranteed or supported by highly rated governments of nations other than the United States. Corporate debt-global includes obligations issued by investment-grade corporations, including some issues that have been guaranteed by governments and government agencies. Asset backed securities consist of triple-A rated securities with cash flows collateralized by credit card receivables and auto loans. Marketable equity securities consist of investments in publicly traded equity securities. The decrease in net unrealized gains in marketable equity securities during the nine-month period ended September 30, 2015 primarily reflects the decrease in market value for certain equity investments subsequent to December 31, 2014 . Duration periods of available-for-sale debt securities at September 30, 2015 were as follows: Amortized Cost Fair Value Duration of one year or less $ 68.1 $ 67.9 Duration of one through three years 292.6 291.9 Duration of three through five years 18.1 18.0 Total $ 378.8 $ 377.8

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory Inventories as of September 30, 2015 and December 31, 2014 are summarized by major category as follows: September 30, 2015 December 31, 2014 Raw materials $ 109.8 $ 200.0 Work in process 131.4 101.5 Finished goods 179.7 91.6 Total $ 420.9 $ 393.1 The decrease in raw materials and increase in finished goods during the nine-month period ended September 30, 2015 was primarily related to the production of ABRAXANE ® to support recently launched new indications. Raw materials for ABRAXANE ® had been at elevated levels at December 31, 2014 and during the nine-month period ended September 30, 2015 many of those materials were converted into finished goods.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible Assets: Our finite lived intangible assets primarily consist of developed product rights and technology obtained from the Pharmion Corp. (Pharmion), Gloucester, Abraxis BioScience, Inc. (Abraxis) and Avila acquisitions. Our indefinite lived intangible assets consist of acquired IPR&D product rights from the Receptos, Nogra and Gloucester acquisitions. The remaining weighted-average amortization period for finite-lived intangible assets not fully amortized is approximately 10.5 years . Intangible assets outstanding as of September 30, 2015 and December 31, 2014 are summarized as follows: September 30, 2015 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,387.1 ) $ 2,018.8 Technology 333.7 (170.8 ) 162.9 Licenses 66.7 (21.2 ) 45.5 Other 44.0 (26.1 ) 17.9 3,850.3 (1,605.2 ) 2,245.1 Non-amortized intangible assets: Acquired IPR&D product rights 8,470.7 — 8,470.7 Total intangible assets $ 12,321.0 $ (1,605.2 ) $ 10,715.8 December 31, 2014 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,234.1 ) $ 2,171.8 Technology 333.7 (135.1 ) 198.6 Licenses 67.0 (18.1 ) 48.9 Other 42.5 (22.9 ) 19.6 3,849.1 (1,410.2 ) 2,438.9 Non-amortized intangible assets: Acquired IPR&D product rights 1,628.7 — 1,628.7 Total intangible assets $ 5,477.8 $ (1,410.2 ) $ 4,067.6 The $6.843 billion increase in the gross carrying value of intangible assets during the nine-month period ended September 30, 2015 was primarily due to the addition of $6.842 billion of IPR&D from the Receptos acquisition. Amortization expense related to intangible assets was $65.0 million and $65.0 million for the three-month periods ended September 30, 2015 and 2014 , respectively, and $195.0 million and $198.8 million for the nine-month periods ended September 30, 2015 and 2014 , respectively. Assuming no changes in the gross carrying amount of intangible assets, the amortization of intangible assets for years 2015 through 2019 is estimated to be in the range of approximately $163.7 million to $306.5 million annually. Goodwill: At September 30, 2015 , our goodwill related to the 2015 acquisition of Receptos, 2014 acquisition of Nogra, the 2012 acquisition of Avila, the 2010 acquisitions of Abraxis and Gloucester, the 2008 acquisition of Pharmion and the 2004 acquisition of Penn T Limited. The carrying value of goodwill increased by $2.551 billion to $4.742 billion as of September 30, 2015 compared to December 31, 2014 due to the Receptos acquisition.

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	Debt Short-Term Borrowings and Current Portion of Long-Term Debt: The carrying value of short-term borrowings and current portion of long-term debt outstanding at September 30, 2015 and December 31, 2014 includes: September 30, 2015 December 31, 2014 Commercial paper $ 699.4 $ 99.6 2.450% senior notes due 2015 500.3 506.3 Total $ 1,199.7 $ 605.9 Long-Term Debt: Summarized below are the carrying values of our senior notes at September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 1.900% senior notes due 2017 $ 503.0 $ 501.0 2.125% senior notes due 2018 999.9 — 2.300% senior notes due 2018 403.8 401.2 2.250% senior notes due 2019 511.3 502.5 2.875% senior notes due 2020 1,497.4 — 3.950% senior notes due 2020 514.6 502.8 3.250% senior notes due 2022 1,032.3 1,010.2 3.550% senior notes due 2022 997.3 — 4.000% senior notes due 2023 722.2 708.5 3.625% senior notes due 2024 1,003.4 996.8 3.875% senior notes due 2025 2,476.1 — 5.700% senior notes due 2040 249.6 249.5 5.250% senior notes due 2043 396.7 396.7 4.625% senior notes due 2044 996.5 996.5 5.000% senior notes due 2045 1,993.8 — Total long-term debt $ 14,297.9 $ 6,265.7 At September 30, 2015 , the fair value of our outstanding Senior Notes was $14.847 billion and represented a Level 2 measurement within the fair value measurement hierarchy. In August 2015, we issued an additional $8.000 billion principal amount of senior notes consisting of $1.000 billion aggregate principal amount of 2.125% Senior Notes due 2018 (the 2018 notes), $1.500 billion aggregate principal amount of 2.875% Senior Notes due 2020 (the 2020 notes), $1.000 billion aggregate principal amount of 3.550% Senior Notes due 2022 (the 2022 notes), $2.500 billion aggregate principal amount of 3.875% Senior Notes due 2025 (the 2025 notes) and $2.000 billion aggregate principal amount of 5.000% Senior Notes due 2045 (the 2045 notes and together with the 2018 notes, the 2020 notes, the 2022 notes, and the 2025 notes, referred to herein as the “2015 issued notes”). The 2015 issued notes were issued at 99.994% , 99.819% , 99.729% , 99.034% , and 99.691% of par, respectively, and the discount is being amortized as additional interest expense over the period from issuance through maturity. Offering costs of approximately $50.0 million have been recorded as debt issuance costs on our Consolidated Balance Sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the 2015 issued notes is payable semi-annually in arrears on February 15 and August 15 each year beginning February 15, 2016 and the principal on each 2015 issued note is due in full at their respective maturity dates. The 2015 issued notes may be redeemed at our option, in whole or in part; the 2018 notes, the 2020 notes, and the 2022 notes may be redeemed at any time, the 2025 notes and 2045 notes may be redeemed at three months and six months prior to the maturity dates, respectively. Early redemption would be at a redemption price equaling accrued and unpaid interest plus the greater of 100% of the principal amount of the 2015 issued notes to be redeemed or the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis plus 20 basis points in the case of the 2018 notes, 20 basis points in the case of the 2020 notes, 25 basis points in the case of the 2022 notes, 30 basis points in the case of the 2025 notes, and 35 basis points in the case of the 2045 notes. If we experience a change of control accompanied by a downgrade of the debt to below investment grade, we will be required to offer to repurchase the 2015 issued notes at a purchase price equal to 101% of their principal amount plus accrued and unpaid interest. We are subject to covenants which limit our ability to pledge properties as security under borrowing arrangements and limit our ability to perform sale and leaseback transactions involving our property. From time to time, we have used treasury rate locks and forward starting interest rate swap contracts to hedge against changes in interest rates in anticipation of issuing fixed-rate notes. As of September 30, 2015 , a balance of $69.7 million in losses remained in accumulated OCI related to these derivative instruments and will be recognized as interest expense over the life of the notes. At September 30, 2015 , we were party to pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes as described in Note 7. Our swap contracts outstanding at September 30, 2015 effectively convert the hedged portion of our fixed-rate notes to floating rates. From time to time we terminate the hedging relationship on certain of our swap contracts by settling the contracts or by entering into offsetting contracts. Any net proceeds received or paid in these settlements are accounted for as a reduction or increase of current and future interest expense associated with the previously hedged notes. As of September 30, 2015 , we had a balance of $34.8 million of unamortized gains recorded as a component of our debt as a result of past swap contract settlements, including $6.0 million related to the settlement of swap contracts during the nine months ended September 30, 2015 . As of December 31, 2014, we had a balance of $38.6 million of unamortized gains recorded as a component of our debt as a result of past swap contract settlements. Commercial Paper: The carrying value of Commercial Paper as of September 30, 2015 and December 31, 2014 was $699.4 million and $99.6 million , respectively, and approximated its fair value. The effective interest rate on our outstanding Commercial Paper at September 30, 2015 was 0.5% . In October 2015, our Board of Directors authorized an increase in the size of our Commercial Paper program from $1.750 billion to $2.750 billion . Credit Facility and Revolving Credit: We maintain a senior unsecured revolving credit facility (Credit Facility) that provides revolving credit in the aggregate amount of $1.750 billion , which was increased from $1.500 billion in April 2015. Also in April 2015, the term of the Credit Facility was extended from April 18, 2018 to April 17, 2020. Subject to certain conditions, we have the right to increase the amount of the Credit Facility (but in no event more than one time per annum) up to a maximum aggregate amount of $2.000 billion . Amounts may be borrowed in U.S. dollars for general corporate purposes. In October 2015, we entered into a revolving credit agreement (Revolving Credit Agreement) with JPMorgan Chase Bank, N.A., under which we may borrow up to a maximum aggregate principal amount of $1.000 billion . The maturity date of any borrowings under the Revolving Credit Agreement and the expiration date of the agreement is December 31, 2015. The Credit Facility and Revolving Credit Agreement currently serve as backup liquidity for our Commercial Paper borrowings. At September 30, 2015 , there was no outstanding borrowing against the Credit Facility or the Revolving Credit Agreement. The Credit Facility and the Revolving Credit Agreement contain affirmative and negative covenants, including certain customary financial covenants. We were in compliance with all financial covenants as of September 30, 2015 .

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We have a stockholder-approved stock incentive plan, the 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (Plan) that provides for the granting of options, restricted stock units (RSUs), performance stock units (PSUs) and other share-based awards to our employees and officers. The Management Compensation and Development Committee of the Board of Directors (Compensation Committee) may determine the type, amount and terms, including vesting, of any awards made under the Plan. During 2015, we increased our usage of PSUs and began issuing PSUs to certain executive officers that are payable in shares of our common stock at the end of a three-year performance measurement period. The number of shares to be issued at the end of the measurement period will vary, based on performance, from 0% to 200% of the target number of PSUs granted, depending on the achievement of specified performance and market targets for revenue ( 37.5% weighting), earnings per share ( 37.5% weighting), and relative total shareholder return ( 25% weighting). All shares delivered upon PSU vesting are restricted from trading for one year and one day from the vesting date. The grant date fair value for the portion of the PSUs related to revenue and earnings per share was estimated using the fair market value of our common stock on the grant date. The grant date fair value for the portion of the PSUs related to relative total shareholder return was estimated using the Monte Carlo valuation model. The weighted average grant date fair value per share of the PSUs granted to certain executive officers during the nine-month period ended September 30, 2015 was $122.90 . The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Cost of goods sold (excluding amortization of acquired intangible assets) $ 8.5 $ 6.8 $ 23.3 $ 18.8 Research and development 65.2 48.4 185.0 141.2 Selling, general and administrative 76.2 56.2 218.1 159.2 Total share-based compensation expense 149.9 111.4 426.4 319.2 Tax benefit related to share-based compensation expense 42.8 31.4 124.0 92.4 Reduction in income $ 107.1 $ 80.0 $ 302.4 $ 226.8 The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2015 (in millions unless otherwise noted): Stock Options Restricted Stock Units Performance- (in thousands) Outstanding at December 31, 2014 77.2 9.4 133 Changes during the Year: Granted 8.7 1.8 211 Exercised / Released (9.0 ) (3.0 ) — Forfeited (1.3 ) (0.3 ) (7 ) Outstanding at September 30, 2015 75.6 7.9 337 Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2015 were as follows (dollars in millions): Stock Options Restricted Stock Units Performance- Based Restricted Stock Units Unrecognized compensation cost $ 613.4 $ 304.3 $ 20.4 Expected weighted-average period in years of compensation cost to be recognized 2.0 1.3 1.7

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We regularly evaluate the likelihood of the realization of our deferred tax assets and reduce the carrying amount of those deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, the carryforward periods available to us for tax reporting purposes and other relevant factors. Significant judgment is required in making this assessment. Our tax returns are under routine examination in many taxing jurisdictions. The scope of these examinations includes, but is not limited to, the review of our taxable presence in a jurisdiction, our deduction of certain items, our claims for research and development credits, our compliance with transfer pricing rules and regulations and the inclusion or exclusion of amounts from our tax returns as filed. Our U.S. federal income tax returns have been audited by the Internal Revenue Service (IRS) through the year ended December 31, 2008. Tax returns for the years ended December 31, 2009, 2010 and 2011 are currently under examination by the IRS, which may conclude within the next twelve months. We are also subject to audits by various state and foreign taxing authorities, including, but not limited to, most U.S. states and major European and Asian countries where we have operations. We regularly reevaluate our tax positions and the associated interest and penalties, if applicable, resulting from audits of federal, state and foreign income tax filings, as well as changes in tax law (including regulations, administrative pronouncements, judicial precedents, etc.) that would reduce the technical merits of the position to below more likely than not. We believe that our accruals for tax liabilities are adequate for all open years. Many factors are considered in making these evaluations, including past history, recent interpretations of tax law and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these evaluations can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We apply a variety of methodologies in making these estimates and assumptions, which include studies performed by independent economists, advice from industry and subject experts, evaluation of public actions taken by the IRS and other taxing authorities, as well as our industry experience. These evaluations are based on estimates and assumptions that have been deemed reasonable by management. However, if management’s estimates are not representative of actual outcomes, our results of operations could be materially impacted. Unrecognized tax benefits, generally represented by liabilities on the Consolidated Balance Sheet and all subject to tax examinations, arise when the estimated benefit recorded in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Virtually all of these unrecognized tax benefits, if recognized, would impact the effective income tax rate. We account for interest and potential penalties related to uncertain tax positions as part of our provision for income taxes. For the nine-month period ended September 30, 2015 gross unrecognized tax benefits increased by $49.8 million , primarily from unrecognized tax benefits related to current year operations of $42.2 million and accrued interest of $7.6 million . The liability for unrecognized tax benefits is expected to increase in the next 12 months relating to operations occurring in that period. Any settlements of examinations with taxing authorities or statute of limitations expirations would likely result in a decrease in our liability for unrecognized tax benefits and a corresponding increase in taxes paid or payable and/or a decrease in income tax expense. Certain examinations may conclude within the next twelve months. It is reasonably possible that the amount of the liability for unrecognized tax benefits could change by a significant amount during the next twelve-month period as a result of settlements or statute of limitations expirations. Finalizing examinations with the relevant taxing authorities can include formal administrative and legal proceedings and, as a result, it is difficult to estimate the timing and range of possible change related to the Company’s unrecognized tax benefits. An estimate of the range of possible change cannot be made until issues are further developed or examinations close. Our estimates of tax benefits and potential tax benefits may not be representative of actual outcomes and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire.

Collaboration Agreements

Collaboration Agreements	9 Months Ended
	Sep. 30, 2015
Collaboration Agreements [Abstract]
Collaboration Agreements	Collaboration Agreements We enter into collaborative arrangements for the research and development, license, manufacture and/or commercialization of products and/or product candidates. In addition, we also acquire product and research and development technology rights and establish research and development collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our research and development capabilities, product pipeline and marketed product base. These arrangements may include non-refundable, upfront payments, payments for options to purchase licenses of additional rights, as well as potential development, regulatory and commercial performance milestone payments, cost sharing arrangements, royalty payments, profit sharing and equity investments. Certain of these arrangements obligate us to make additional equity investments in the event of an initial public offering of equity by our partners. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success. Although we do not consider any individual alliance to be material, certain of the more notable alliances are described below. See Note 17 of Notes to Consolidated Financial Statements included in our 2014 Annual Report on Form 10-K for a description of certain other collaboration agreements entered into prior to January 1, 2015 . The following is a brief description of significant developments in the relationships between Celgene and our collaboration partners during the nine months ended September 30, 2015 : Agios Pharmaceuticals, Inc. (Agios): During 2010, we entered into a discovery and development collaboration and license agreement with Agios that focuses on cancer metabolism targets and the discovery, development and commercialization of associated therapeutics. We have an exclusive option to license any potential products that result from the Agios cancer metabolism research platform through the end of phase I clinical trials. With respect to each product that we choose to license, Agios could receive up to approximately $120.0 million upon achievement of certain milestones and other payments plus royalties on worldwide sales, and Agios may also participate in the development and commercialization of certain products in the United States. In December 2014, we elected to extend the collaboration and license agreement for an additional year for a payment of $20.0 million . Our option to license products will terminate on April 14, 2016. In June 2014, we exercised our option to license AG-221 from Agios on an exclusive worldwide basis, with Agios retaining the right to conduct a portion of commercialization activities for AG-221 in the United States. AG-221 is currently in a phase I study in patients that present an isocitrate dehydrogenase-2 (IDH2) mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML). In January 2015, we exercised our option, subject to applicable regulatory approvals which were subsequently achieved, to an exclusive license from Agios to AG-120 outside the United States, with Agios retaining the right to conduct development and commercialization within the United States. AG-120 is an orally available, selective inhibitor of the mutated isocitrate dehydrogenase-1 (IDH1) protein for the treatment of patients with cancers that harbor an IDH1 mutation. AG-120 is currently being evaluated in two phase I dose escalation trials, one in advanced hematological malignancies and the other in advanced solid tumors. In April 2015, we and Agios entered into a new joint worldwide development and profit share collaboration for AG-881. AG-881 is a small molecule that has shown in preclinical studies to fully penetrate the blood brain barrier and inhibit IDH1 and IDH2 mutant cancer cells. Under the terms of the AG-881 collaboration, Agios received an initial payment of $10.0 million and is eligible to receive contingent payments of up to $70.0 million based on the attainment of specified regulatory goals. The upfront payment to Agios was accounted for as $9.0 million of upfront research and development collaboration expense and $1.0 million of prepaid manufacturing rights recorded on the balance sheet. We and Agios will jointly collaborate on the worldwide development program for AG-881, sharing development costs equally. The two companies will share profits equally, with Celgene recording commercial sales worldwide. Agios will lead commercialization in the U.S. with both companies sharing equally in field-based commercial activities, and we will lead commercialization ex-U.S. with Agios providing one third of field-based commercial activities in the major EU markets. Epizyme Inc. (Epizyme): In July 2015 we entered into an amendment and restatement of the collaboration and license agreement dated April 2, 2012 with Epizyme (the “Amended Agreement”). Under the original agreement, we had an exclusive license, for all countries other than the United States, to small molecule HMT inhibitors targeting DOT1L, including pinometostat (EPZ-5676), and an option, on a target-by-target basis, to exclusively license, for all countries other than the United States, rights to small molecule HMT inhibitors targeting any other HMT targets. Under the Amended Agreement: • We retain our exclusive license to small molecule HMT inhibitors targeting DOT1L outside of the United States, including pinometostat (EPZ-5676), • We have narrowed our option rights to HMT inhibitors targeting three predefined targets (the “Option Targets”), • The exclusive licenses to HMT inhibitors targeting two of the Option Targets that we may acquire have been expanded to include the United States, with the exclusive license to the third Option Target continuing to be for all countries other than the United States, • Our option period has been extended for each of the Option Targets and is exercisable at the time of Epizyme's IND filing for an HMT inhibitor targeting the applicable Option Target, • Epizyme may complete phase I clinical trials as to each Option Target following our exercise of our option at IND filing. If Epizyme chooses not to complete phase I clinical trials to an Optioned Target, future milestones and royalties on products developed for such Option Targets will be reduced. Under the terms of the Amended Agreement, we made a $10.0 million payment to Epizyme. In addition, Epizyme may earn up to $75.0 million in development milestone payments, up to $365.0 million in regulatory milestone payments and up to $170.0 million in sales milestone payments related to the Option Targets. For the DOT1L program, Epizyme remains eligible to earn $35.0 million in clinical development milestone payments and up to $100.0 million in regulatory milestone payments. Epizyme is also entitled to tiered royalties ranging from the mid-single digits to the mid-teens on annual net product sales in our territory, subject to reductions in specified circumstances. The Amended Agreement extends the research and development collaboration for at least an additional three years until July 8, 2018, subject to our exercise of our options at IND filing. The Amended Agreement will expire on a product-by-product and country-by-country basis on the date of the expiration of the applicable royalty term with respect to each licensed product in each country and in its entirety upon the expiration of all applicable royalty terms for all licensed products in all countries. We have the right to terminate the Amended Agreement in its entirety or with respect to one or more Optioned Targets upon 120 days’ notice. Upon the expiration of the royalty term of a particular license product, we will have a fully paid-up, royalty-free license to use Epizyme intellectual property to manufacture, market, use and sell such licensed products in our territory. bluebird bio, Inc. (bluebird): In June 2015, we amended and restated the March 2013 collaboration agreement with bluebird. The amended and restated collaboration will focus on the discovery, development and commercialization of novel disease-altering gene therapy product candidates targeting B-cell maturation antigen (BCMA). BCMA is a cell surface protein that is expressed in normal plasma cells and in most multiple myeloma cells, but is absent from other normal tissues. The collaboration applies gene therapy technology to modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells that express BCMA. We have an option to license any anti-BCMA products resulting from the collaboration after the completion of a phase I clinical study by bluebird. Under the amended and restated collaboration agreement we made an additional $25.0 million payment for bluebird to develop the lead anti-BCMA product candidate (bb2121) through a phase I clinical study and to develop next-generation anti-BCMA product candidates. The payment was recorded as prepaid research and development on the balance sheet and is being recognized as expense as development work is performed. Upon exercising our option to license a product and achievement of certain milestones, we may be obligated to pay up to $230.0 million per licensed product in aggregate potential option fees and clinical and regulatory milestone payments. bluebird also has the option to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the United States in exchange for a reduction of milestone payments. Royalties would also be paid to bluebird in regions where there is no profit share, including in the United States, if bluebird declines to exercise their co-development and profit sharing rights. We have the ability to terminate the collaboration at our discretion upon 90 days written notice to bluebird. If a product is optioned, the parties will enter into a pre-negotiated license agreement and potentially a co-development agreement should bluebird exercise its option to participate in the development and commercialization in the United States. The license agreement, if not terminated sooner, would expire upon the expiration of all applicable royalty terms under the agreement with respect to the particular product, and the co-development agreement, if not terminated sooner, would expire when the product is no longer being developed or commercialized in the United States. Upon the expiration of a particular license agreement, we will have a fully paid-up, royalty-free license to use bluebird intellectual property to manufacture, market, use and sell such licensed product. FORMA Therapeutics Holdings, LLC (FORMA): In April 2013, we entered into a collaboration agreement with FORMA to discover, develop and commercialize drug candidates to regulate protein homeostasis targets. Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. The collaboration was launched with an upfront payment that enables us to evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, we have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the United States, in exchange for research and early development payments of up to approximately $200.0 million to FORMA. Under the terms of the collaboration agreement, FORMA is incentivized to advance the full complement of drug candidates through phase I, while Celgene is responsible for all further global clinical development for each licensed candidate. FORMA is eligible to receive up to an additional $315.0 million in potential payments based upon development, regulatory and sales objectives for the first ex-U.S. license. FORMA is also eligible to receive potential payments for successive licenses, which escalate for productivity, increasing up to a maximum of an additional $430.0 million per program. In addition, FORMA will receive royalties on ex-U.S. sales and additional payments if multiple drug candidates reach defined cumulative sales objectives. The collaboration agreement includes provisions for Celgene to obtain rights with respect to development and commercialization of drug candidates inside the United States in exchange for additional payments. Under the collaboration, the parties perform initial research and development for a term of four years . If, during such research term, a drug candidate meets certain criteria, then the parties enter into a pre-negotiated license agreement and the collaboration continues until all license agreements have expired and all applicable royalty terms under the collaboration with respect to the particular products have expired. Each license agreement, if not terminated sooner, expires upon the expiration of all applicable royalty terms under such agreement. Upon the expiration of each license agreement, we will have an exclusive, fully-paid, royalty-free license to use the applicable FORMA intellectual property to manufacture, market, use and sell the product developed under such agreement outside of the United States. In October, 2013, we entered into the first ex-US license with FORMA and paid the applicable upfront payment under such license. In February, 2015, we entered into the second ex-US license with FORMA and made a $19.0 million upfront payment for the license. On March 21, 2014, we entered into a second collaboration arrangement with FORMA, pursuant to which FORMA granted us an option, for an additional fee, to license the rights to select current and future FORMA drug candidates during a term of three and one half years. We agreed to pay an upfront payment of $225.0 million . In addition, with respect to each subsequently licensed drug candidate, we have the obligation to pay designated amounts when certain development, regulatory and sales milestone events occur, with such amounts being variable and contingent on various factors. With respect to each licensed drug candidate, we assume responsibility for all global development activities and costs after completion of phase I clinical trials. FORMA retains U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization. Under this collaboration arrangement, we also have an option to enter into up to two additional collaborations with successive terms of two years each for additional payments totaling approximately $375.0 million . If we exercise our option to enter into both of these additional collaborations, we will receive an exclusive option to acquire FORMA, including the U.S. rights to all licensed drug candidates, and worldwide rights to other wholly owned assets within FORMA at that time. In April, 2015, we entered into the first license with FORMA under the second collaboration and made a $20.0 million upfront payment for the license. MorphoSys AG (MorphoSys): On March 26, 2015, we and MorphoSys agreed to terminate our collaboration, license and equity purchase agreement for the co-development and co-promotion of the anti-CD38 antibody, MOR202. As part of the termination, we made a final payment of $8.1 million to settle all obligations. The termination of our agreement eliminates all potential future payments for development, regulatory and sales milestones. We have retained our equity interest in MorphoSys. AstraZeneca PLC (AstraZeneca): In April 2015, we entered into a strategic collaboration agreement with MedImmune Limited (MedImmune), a subsidiary of AstraZeneca, to develop and commercialize MEDI4736, a novel anti-PD-L1 monoclonal antibody, for hematologic malignancies. The agreement provides for a negotiation period to expand the agreement for other immuno-therapeutics. Under the terms of the agreement, we made an upfront payment of $450.0 million to MedImmune. We lead clinical development across all new clinical trials within the collaboration and are responsible for all costs associated with such trials until December 31, 2016, after which we will be responsible for 75 percent of those costs. We also will be responsible for the global commercialization of approved MEDI4736 indications in hematology, and will receive royalty rates starting at 70 percent of worldwide sales from all uses in hematology. Royalty rates will decrease gradually to 50 percent over a period of 4 years after the start of commercial sales. The agreement may be terminated at our discretion upon nine months’ prior written notice to MedImmune, and by either party upon material breach of the other party, subject to cure periods. The agreement, if not terminated sooner, expires upon the expiration of all applicable royalty terms under such agreement. Lycera Corp. (Lycera): In June 2015, we entered into a collaboration and option agreement with Lycera. Under the agreement, the parties will support the development of Lycera’s portfolio of immune modulator assets, including (1) oral agonists that target ROR y , a master control switch of immune system activation, for the potential treatment of a broad range of cancers, and (2) LYC-30937, an oral gut-directed ATPase modulator currently in phase I clinical studies. Lycera has developed orally bioavailable ROR y agonists that have demonstrated single agent therapeutic activity in multiple animal models of cancer. Ex-vivo treatment with ROR y agonist compounds has been shown to enhance the therapeutic benefit of adoptive T-cell therapy by improving both immune cell persistence and activation. Development of LYC-30937 is focused on the treatment of inflammatory bowel disease, with the goal of delivering significant disease improvement without global immune suppression. Under the collaboration, Lycera also will continue to advance its other programs, including a Rho-associated protein kinase 2 (ROCK2) inhibitor. Under the terms of the agreement, we made an upfront payment of $82.5 million to Lycera. We received an exclusive option for an additional fee to license Lycera’s portfolio of ex-vivo ROR y agonist compounds, an equity interest and an exclusive right to acquire Lycera. If we exercise the acquisition right, Lycera shareholders will be also eligible to receive future success-based milestone payments of up to $190.0 million . The upfront payment to Lycera was accounted for as $69.5 million of upfront collaboration payment included in research and development expense and $13.0 million as non-current assets consisting of $10.0 million for an equity investment and $3.0 million for a warrant to acquire the remaining shares outstanding. The agreement has an initial term of 3 years and may be terminated earlier at our discretion upon 6 months’ prior written notice to Lycera and by either party upon material breach of the other party, subject to cure periods. Juno Therapeutics, Inc. (Juno): In June 2015, we announced a collaboration and investment agreement with Juno for the development and commercialization of immunotherapies for cancer and autoimmune diseases. The collaboration and investment agreement became effective on July 31, 2015 after an early termination of the Hart-Scott-Rodino Antitrust waiting period. Under the terms of the agreement, we have the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR T-cell product candidates. For Juno-originated programs co-developed under the collaboration, (a) Juno will be responsible for research and development in North America and will retain commercialization rights in those territories, (b) we will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories, and (c) we have certain co-promotion options for global profit sharing arrangements under which the parties will share worldwide expenses and profits equally, except in China. Juno will have the option to enter into co-development and co-commercialization arrangements on certain Celgene-originated development candidates that target T-cells. For any such Celgene-originated programs co-developed under the collaboration, (a) the parties will share global costs and profits, with 70 percent allocated to us and 30 percent allocated to Juno, and (b) we will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, we made a $1.000 billion payment to Juno and received 9.1 million shares of Juno common stock, amounting to approximately 9 percent of Juno's outstanding common stock. The value of our investment in Juno common stock of $424.9 million was recorded as an available-for sale marketable security based on the market price of the stock on the date of closing and the remaining portion of the $1.000 billion payment, which consists of both a $150.0 million upfront payment and a $425.1 million premium paid on our equity investment, was recorded to research and development expense. The collaboration agreement has an initial term of ten years. If the parties enter into any pre-negotiated license or co-commercialization agreement during the initial term, the collaboration agreement will continue until all such license and co-commercialization agreements have expired. The collaboration agreement may be terminated at our discretion upon 120 days’ prior written notice to Juno and by either party upon material breach of the other party, subject to cure periods. Nurix, Inc. (Nurix): In September 2015, we entered into a strategic collaboration agreement with Nurix for the discovery, development and commercialization of novel small molecule therapeutics in oncology and inflammation and immunology. Nurix will work exclusively with us in these therapeutic areas to advance new therapies that function through the ubiquitin proteasome system (UPS) to modulate protein homeostasis, a fundamental cellular process controlling protein levels. Under the terms of the collaboration, we made an upfront payment to Nurix of $149.8 million , plus an equity investment of $17.0 million , which amounted to approximately 13 percent of Nurix outstanding equity, for an option to license future programs. The option term for each of these programs is the earlier of either (a) 45 days after the delivery of a phase I data package, or (b) four years, which period we may extend twice for the payment of additional fees. During the term, Nurix may focus on investigating E3 ubiquitin ligases and E2 conjugating enzymes to identify the most promising drug discovery programs for use in oncology or inflammation and immunology therapeutic applications. Nurix will control and is responsible for all drug discovery and development activities through the end of phase I clinical trials. We may opt to license global development and commercialization rights to a program in exchange for an option fee, potential clinical, regulatory and sales milestone payments totaling up to $405.0 million , as well as future tiered single-digit to low double-digit royalties on global sales. We would also have worldwide rights to collaboration products, with the exception of certain collaboration products for which Nurix would retain U.S. development and commercialization rights. These rights include the opportunity for the companies to co-develop and co-commercialize up to two programs in the U.S., sharing profits and losses equally, and we would retain ex-US rights, in exchange for an option fee, milestone payments and royalties on ex-U.S. sales on a program-by-program basis. For candidates not optioned by us under the collaboration, Nurix would retain worldwide rights. Acetylon Pharmaceuticals, Inc. (Acetylon) : In August 2015, we entered into an amendment to the collaboration and option agreement with Acetylon to extend the expiration date of the agreement to May 2, 2016 and remove our right to further extend the expiration date. In addition to the collaboration arrangements described above, we entered into a number of collaborative arrangements during the nine-months ended September 30, 2015 that include the potential for future milestone payments of up to an aggregate $120.0 million related to the attainment of specified developmental, regulatory and sales milestones over a period of several years. Our obligation to fund these efforts is contingent upon our continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs. A financial summary of certain period activity related to our collaboration agreements is presented below 1,2 : Three-Month Periods Ended September 30, Research and Development Expense Upfront Fees Milestones Extension/Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Acetylon 2015 $— $— $— $5.4 $— 2014 — — — 4.3 — bluebird 2015 — — — 2.1 — 2014 — — — 0.1 — Epizyme 2015 — — 10.0 — — 2014 — — — — — Juno 2015 575.1 — — — 424.9 Nurix 2015 149.8 — — — 17.0 Sutro 2015 — — — 1.4 — 2014 72.6 — — 0.1 11.9 Other Collaboration Arrangements 2015 26.9 — — — — 2014 6.0 6.8 — 0.4 27.0 Nine-Month Periods Ended September 30, Research and Development Expense Upfront Fees Milestones Extension/Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Acceleron 2015 $— $— $— $— $— 2014 — — — — 52.4 Acetylon 2015 — — — 14.6 — 2014 — — — 11.4 — Agios 2015 9.0 — — — — 2014 — — — — 13.0 AstraZeneca 2015 450.0 — — — — bluebird 2015 — — — 2.8 — 2014 — — — 0.1 — Epizyme 2015 — — 10.0 — — 2014 — — — — 9.9 FORMA 2015 39.0 — — — — 2014 225.0 — — 0.1 — Juno 2015 575.1 — — — 424.9 Lycera 2015 69.5 — — — 10.0 MorphoSys 2015 — — 8.1 — — 2014 — — — — — NantBioScience (3) 2015 — — — — — 2014 50.0 — — — 90.0 Nurix 2015 149.8 — — — 17.0 Sutro 2015 — — — 3.4 — 2014 72.6 — — 0.2 11.9 Other Collaboration Arrangements 2015 47.9 8.0 — 0.9 50.0 2014 54.0 7.3 — 6.9 47.9 A financial summary of the period-end balances related to our collaboration agreements is presented below: Balances as of: Intangible Asset Balance Equity Investment Balance Percentage of Outstanding Equity Acceleron September 30, 2015 $— $114.8 14% December 31, 2014 — 179.7 14% Acetylon September 30, 2015 5.8 25.0 11% December 31, 2014 20.4 25.0 10% Agios September 30, 2015 1.0 370.1 13% December 31, 2014 — 587.4 14% bluebird September 30, 2015 22.3 N/A N/A December 31, 2014 0.1 N/A N/A Epizyme September 30, 2015 — 47.3 8% December 31, 2014 — 69.3 11% FORMA September 30, 2015 0.1 N/A N/A December 31, 2014 0.1 N/A N/A Juno September 30, 2015 — 371.8 9% Lycera September 30, 2015 3.0 10.0 8% MorphoSys September 30, 2015 — 53.1 3% December 31, 2014 — 73.9 3% NantBioScience September 30, 2015 — 90.0 13% December 31, 2014 — 90.0 14% Nurix September 30, 2015 0.2 17.0 13% Sutro September 30, 2015 24.4 17.6 15% December 31, 2014 12.8 17.6 15% Other Collaboration Arrangements September 30, 2015 22.1 130.1 N/A December 31, 2014 34.4 90.8 N/A 1 Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2014 Annual Report on Form 10-K if there has been new significant activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements. 2 In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us. 3 $25.0 million of expense related to the settlement of contingent matching contributions was also recognized at the 2014 inception of the collaboration agreement with NantBioScience and included in Selling, General and Administrative expense.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Collaboration Arrangements: We have entered into certain research and development collaboration agreements with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial targets. Our obligation to fund these efforts is contingent upon continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs. Due to the nature and uncertainty of these arrangements and any future potential payments, no amounts have been recorded in our accompanying Consolidated Balance Sheets at September 30, 2015 and December 31, 2014 . See Note 14 for additional details related to collaboration arrangements. Contingencies: We believe we maintain insurance coverage adequate for our current needs. Our operations are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the air and water and establish standards for the treatment, storage and disposal of solid and hazardous wastes. We review the effects of such laws and regulations on our operations and modify our operations as appropriate. We believe we are in substantial compliance with all applicable environmental laws and regulations. We have ongoing customs, duties and VAT examinations in various countries that have yet to be settled. Based on our knowledge of the claims and facts and circumstances to date, none of these matters, individually or in the aggregate, are deemed to be material to our financial condition.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2015
Legal Proceedings
Legal Proceedings	Legal Proceedings We have from time to time received inquiries and subpoenas and other types of information requests from government authorities and others and we have been subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, product recalls, costs and significant payments, which may have a material adverse effect on our results of operations, cash flows or financial condition. Pending patent proceedings include challenges to the scope, validity and/or enforceability of our patents relating to certain of our products, uses of products or processes. Further, we are subject to claims of third parties that we infringe their patents covering products or processes. Although we believe we have substantial defenses to these challenges and claims, there can be no assurance as to the outcome of these matters and an adverse decision in these proceedings could result in one or more of the following: (i) a loss of patent protection, which could lead to a significant reduction of sales that could materially affect future results of operations, (ii) our inability to continue to engage in certain activities, and (iii) significant liabilities, including payment of damages, royalties and/or license fees to any such third party. Among the principal matters pending are the following: Patent Related Proceedings: REVLIMID ® : We received Notice Letters, dated August 30, 2010 and June 12, 2012 from Natco Pharma Limited of India (Natco) notifying us of Natco’s Abbreviated New Drug Application (ANDA), which contain Paragraph IV certifications against certain of Celgene’s patents that are listed in the FDA Approved Drug Products With Therapeutic Equivalence Evaluations (the “Orange Book”) for REVLIMID ® (lenalidomide). Natco’s Notice Letters were sent in connection with its filing of an ANDA seeking permission from the FDA to market a generic version of 25mg, 15mg, 10mg and 5mg REVLIMID ® capsules. We filed separate infringement actions (which were subsequently consolidated) in the United States District Court for the District of New Jersey against Natco, Natco’s U.S. partner, Arrow International Limited (Arrow), and Arrow’s parent company, Watson Laboratories, Inc. (Watson, a wholly-owned subsidiary of Allergan plc (formerly known as Actavis, Inc.) and formerly known as Watson Pharmaceuticals, Inc.) (Natco, Arrow and Watson are collectively referred to hereinafter as “Natco”). In its answer and counterclaim, Natco asserts that our patents are invalid, unenforceable and/or not infringed by Natco’s proposed generic products. The patents in dispute include United States Patent Nos. 5,635,517; 6,045,501; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 7,119,106; 7,465,800; 6,281,230; 7,189,740; 7,968,569; 8,288,415; 8,315,886 and 8,404,717, plus three non-Orange Book listed patents, United States Patent Nos. 7,977,357; 8,193,219 and 8,431,598. A claim construction decision was issued on May 27, 2014, and fact discovery closed on August 4, 2014. On November 18, 2014, the court granted-in-part Natco’s motion to amend its invalidity contentions, and denied Celgene’s appeal of that decision on July 9, 2015. Expert discovery has been extended and is set to close on January 15, 2016. No trial date has been set. We received a third Notice Letter from Natco dated April 3, 2014, notifying us of Natco’s Paragraph IV certifications against five patents, including United States Patent Nos. 8,404,717 (already in suit), 8,530,498; 8,589,188; 8,626,531; and 8,648,095. On May 15, 2014, we filed an infringement action in the United States District Court for the District of New Jersey against Natco, Arrow and Watson. Natco filed its answer and counterclaim on June 13, 2014, and asserts that our patents are invalid, unenforceable and/or not infringed by Natco’s proposed generic products. Fact discovery is set to close on November 6, 2015. No trial date has been set. We believe that Natco’s defenses and counterclaims in both cases are unlikely to be sustained and we intend to vigorously assert our patent rights. Although there can be no assurance as to the ultimate outcomes of these proceedings, we currently expect that they will not have a material adverse effect on our financial condition or results of operations. However, if Natco is successful in challenging all the patents in dispute or if the court rules that certain of our key patent claims are invalid or not infringed, such events could have a material adverse effect on our financial condition and results of operations. THALOMID ® and REVLIMID ® : On October 2, 2013, Andrulis Pharmaceuticals Corporation (Andrulis) filed a lawsuit against us in the United States District Court for the District of Delaware claiming infringement of U.S. Patent No. 6,140,346 (“the ‘346 patent”). Andrulis alleges that we are liable for infringement of one or more claims of the ‘346 patent, which covers the use of THALOMID ® (and, as asserted by Andrulis, REVLIMID ® ) in combination with an alkylating agent (e.g., melphalan) to treat cancers. Andrulis is seeking an unspecified amount of damages, attorneys’ fees and injunctive relief. We disagree with Andrulis’ allegations and intend to vigorously defend against this infringement suit. On January 30, 2014, we filed a motion to dismiss Andrulis’ amended complaint. On April 11, 2014, the court denied our motion in part and granted our motion in part, dismissing two of Andrulis' four infringement claims without leave to amend. We filed an answer to the remaining claims on April 25, 2014. In February 2015, we filed a partial summary judgment motion. The court held hearings on claim construction and on the partial summary judgment motion on May 27, 2015 and May 28, 2015, respectively. On June 26, 2015, the court issued its claim construction ruling and held that certain claim terms were indefinite. On July 28, 2015, the court entered final judgment in favor of Celgene. On August 27, 2015, Andrulis filed a notice of appeal to the United States Court of Appeals for the Federal Circuit on the final judgment and its indefiniteness and claim construction rulings. ISTODAX® (romidepsin): We received a Notice Letter dated March 17, 2014 from Fresenius Kabi USA, LLC (Fresenius) notifying us of Fresenius’s ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against U.S. Patent Nos. 7,608,280 and 7,611,724 (the ‘280 and ‘724 patents) that are listed in the Orange Book for ISTODAX ® . On April 30, 2014, Celgene and Astellas Pharma Inc. (Astellas), filed an infringement action in the United States District Court for the District of Delaware against Fresenius. In its answer and counterclaim, Fresenius asserts that the ‘280 and ‘724 patents are invalid and/or not infringed by its proposed generic products. As a result of the filing of our action, the FDA cannot grant final approval of Fresenius’s ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) May 5, 2017. Celgene and Astellas have reached an agreement to settle all claims and counterclaims with Fresenius. Under the terms of the settlement agreement, which was approved by the court, the parties have stipulated to dismiss the case and Celgene will provide Fresenius a non-exclusive, royalty-free sublicense to manufacture and market the Fresenius generic product as of February 1, 2018. The settlement agreement has been submitted to the Federal Trade Commission for review. On August 4, 2014, we received a Notice Letter from InnoPharma, Inc. (InnoPharma) notifying us of Innopharma's ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against the '280 and '724 patents. On September 12, 2014, we and Astellas, filed an infringement action in the United States District Court for the District of Delaware against InnoPharma. In its answer and counterclaim, InnoPharma asserts that the ‘280 and ‘724 patents are invalid and/or not infringed by its proposed generic products. As a result of the filing of our action, the FDA cannot grant final approval of InnoPharma's ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) May 5, 2017. Fact discovery is set to close on November 6, 2015 and the claim construction hearing is scheduled for November 17, 2015. Expert discovery is set to close on July 13, 2016 and trial is scheduled to begin on September 19, 2016. On May 28, 2015, we received a Notice Letter from Teva Pharmaceuticals USA, Inc. (Teva) notifying us of Teva’s ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against the '280 and '724 patents. On July 10, 2015, we and Astellas filed an infringement action in the United States District Court for the District of Delaware against Teva. Teva has not yet responded. As a result of the filing of our action, the FDA cannot grant final approval of Teva’s ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) November 28, 2017. Fact discovery is set to close on August 9, 2016. A claim construction hearing is scheduled for August 23, 2016. Expert discovery is set to close on April 18, 2017 and trial is scheduled to begin on June 19, 2017. On October 30, 2015, we received a Notice Letter from Teva notifying us of Teva’s New Drug Application that seeks approval from the FDA to engage in the commercial manufacture, use or sale of romidepsin for injection. The NDA was filed pursuant to FDC Act § 505(b)(3)(D)(i). The Notice Letter contains Paragraph IV certifications against the '280 and '724 patents. THALOMID ® (thalidomide): We received a Notice Letter dated December 18, 2014 from Lannett Holdings, Inc. (Lannett) notifying us of Lannett’s ANDA which contains Paragraph IV certifications against U.S. Patent Nos. 5,629,327; 6,045,501; 6,315,720; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 6,908,432; 7,141,018; 7,230,012; 7,435,745; 7,874,984; 7,959,566; 8,204,763; 8,315,886; 8,589,188; and 8,626,531 that are listed in the Orange Book for THALOMID ® (thalidomide). Lannett is seeking to market generic versions of 50mg, 100mg, 150mg and 200mg of THALOMID ® capsules. On January 30, 2015, we filed an infringement action against Lannett in the United States District Court for the District of New Jersey. On March 27, 2015, Lannett filed a motion to dismiss our complaint for lack of personal jurisdiction. Following oral argument on July 27, 2015, the court ordered Lannett to provide jurisdictional discovery. Other Proceedings: In 2009, we received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) seeking documents and other information relating to requests by manufacturers of generic drugs to purchase our patented REVLIMID ® and THALOMID ® brand drugs in order for the FTC to evaluate whether there may be reason to believe that we have engaged in unfair methods of competition. In 2010, the State of Connecticut issued a subpoena referring to the same issues raised by the 2009 CID. Also in 2010, we received a second CID from the FTC relating to this matter. We continue to cooperate with the FTC and State of Connecticut investigations. On April 3, 2014, Mylan Pharmaceuticals Inc. (Mylan) filed a lawsuit against us in the United States District Court for the District of New Jersey alleging that we violated various federal and state antitrust and unfair competition laws by allegedly refusing to sell samples of our THALOMID ® and REVLIMID ® brand drugs so that Mylan can conduct the bioequivalence testing needed to submit ANDAs to the FDA for approval to market generic versions of these products. Mylan is seeking injunctive relief, damages and declaratory judgment. We filed a motion to dismiss Mylan’s complaint on May 25, 2014. Mylan filed its opposition to our motion to dismiss on June 16, 2014. The Federal Trade Commission filed an amicus curiae brief in opposition to our motion to dismiss on June 17, 2014. On December 22, 2014, the court granted Celgene’s motion to dismiss (i) Mylan’s claims based on Section 1 of the Sherman Act (without prejudice), and (ii) Mylan's claims arising under the New Jersey Antitrust Act. The court denied our motion to dismiss the rest of the claims which primarily relate to Section 2 of the Sherman Act. On January 6, 2015 we filed a motion to certify for interlocutory appeal the order denying our motion to dismiss with respect to the claims relating to Section 2 of the Sherman Act, which appeal was denied by the United State Court of Appeals for the Third Circuit on March 5, 2015. On January 20, 2015, we filed an answer to Mylan’s complaint. Fact discovery is set to close February 2, 2016 and expert discovery is set to be completed by July 31, 2016. No trial date has been set. We intend to vigorously defend against Mylan’s claims. In 2011, the United States Attorney’s Office for the Central District of California informed us that they were investigating possible off-label marketing and improper payments to physicians in connection with the sales of THALOMID ® and REVLIMID ® . In 2012, we learned that two other United States Attorneys’ offices (the Northern District of Alabama and the Eastern District of Texas) and various state Attorneys General were conducting related investigations. In February 2014, three civil qui tam actions related to those investigations brought by three former Celgene employees on behalf of the federal and various state governments under the federal false claims act and similar state laws were unsealed after the United States Department of Justice (DOJ) declined to intervene in any of these actions. The DOJ retains the right to intervene in these actions at any time. Additionally, while several states have similarly declined to intervene in some of these actions, they also retain the right to intervene in the future. The plaintiffs in the Northern District of Alabama and Eastern District of Texas actions have voluntarily dismissed their cases. On April 25, 2014, we filed a motion to dismiss the complaint in the remaining (Central District of California) action, United States of America ex. rel. Beverly Brown V. Celgene Corp. , unsealed February 5, 2014 (the Brown Action), which was denied except with respect to certain state claims. We filed our answer to the complaint on August 28, 2014. Expert discovery is set to close on November 20, 2015. Summary judgment motions are due January 29, 2016. No trial date has been set. We intend to vigorously defend against the remaining claims in the Brown Action. In a related matter, in July 2014, we received a letter purportedly on behalf of two stockholders that demands, primarily on the basis of the allegations in the Brown Action, that our board of directors take action on the Company’s behalf to correct alleged deficiencies in the Company’s internal controls and to recover from current and past directors and officers damages those stockholders allege to have resulted from breaches of fiduciary duties related to the matters alleged in the Brown Action. Our Board formed a Demand Investigation Committee, and with the assistance of independent counsel retained by it, the Demand Investigation Committee considered the issues raised in the stockholders’ letter. In October 2015, the Demand Investigation Committee reported to the Board of Directors, and the Board of Directors accepted the Committee’s recommendation, that the Company take no action at this time, legal or otherwise, in response to the stockholders’ demands. In November 2014, we received another letter purportedly on behalf of a stockholder that demanded access to certain books and records of the Company for the purpose of investigating matters pertaining to the Brown Action. The Company has complied with the demand to the extent it considers reasonable in view of the Demand Investigation Committee’s consideration of matters pertaining to the Brown Action. On June 7, 2013, Children's Medical Center Corporation (CMCC) filed a lawsuit against us in the Superior Court of the Commonwealth of Massachusetts alleging that our obligation to pay a 1% royalty on REVLIMID ® net sales revenue and a 2.5% royalty on POMALYST ® /IMNOVID ® net sales revenue under a license agreement entered into in December 2002 extended beyond February 28, 2013 and that our failure to make royalty payments to CMCC subsequent to February 28, 2013 breached the license agreement. CMCC is seeking unspecified damages and a declaration that the license agreement remains in full force and effect. In July 2013, we removed these proceedings to the United States District Court for the District of Massachusetts. On August 5, 2013, we filed an answer to CMCC’s complaint and a counterclaim for declaratory judgment that our obligations to pay royalties have expired. On August 26, 2013, CMCC filed an answer to our counterclaim. On July 8, 2014, CR Rev Holdings, LLC (“CR Rev”) filed a complaint against Celgene in the same action. CR Rev alleges that CMCC sold and assigned a substantial portion of the royalty payments owed by Celgene on the sale of REVLIMID ® to CR Rev. CR Rev has alleged causes of action with respect to REVLIMID ® identical to those alleged by CMCC, and seeks unspecified damages and a declaration that the license agreement is still in effect. Discovery in this matter has been completed. On August 4, 2015, Plaintiffs filed a motion for summary judgment on certain claims, including breach of contract, declaratory judgment and, with respect to Celgene’s counterclaims, patent misuse. Oral argument on Plaintiffs’ motion for summary judgment was held on October 21, 2015. No trial date has as yet been set by the court. We intend to vigorously defend against CMCC's and CR Rev’s claims. As of September 30, 2015, we consider the range of reasonably possible loss relating to this lawsuit to be between zero and $126.3 million , with the high end of the range being the royalty payments on REVLIMID ® we would have made to CMCC under the license agreement through September 30, 2015, if our obligation to pay royalties remained in effect. CMCC contends that our royalty obligation continues on net sales of REVLIMID ® , as well as POMALYST ® /IMNOVID ® , at least until May 2016 and if CMCC prevails, we may be obligated to continue to pay royalties on sales for periods after September 30, 2015. In the second quarter of 2014, we received a Health Insurance Portability and Accountability Act (HIPAA) subpoena from the United States Attorney’s Office for the District of Massachusetts requesting certain documents relating to an investigators meeting in 2011 with respect to a clinical study relating to ABRAXANE ® . The Company cooperated with the United States Attorney's Office in connection with this subpoena and we understand that the matter is no longer active. On October 2, 2014, a complaint was filed in Delaware Chancery Court by a stockholder asserting derivative claims on behalf of the Company against the non-employee members of the Board of Directors. The complaint, as subsequently amended, alleged that equity grants made to non-employee directors in 2012, 2013 and 2014 were excessive compared to the equity grants to directors of peer companies, and that the award of such allegedly excessive compensation constituted a breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On September 14, 2015, the parties agreed to settle all claims in the case, subject to the Chancery Court’s approval of the settlement. A hearing on the settlement is scheduled for December 9, 2015. The settlement provides prospective relief only, setting limits on equity grants to non-employee directors for at least four years and requiring certain changes in the charter of the Board’s compensation committee and in the timing of disclosures concerning non-employee director compensation. On November 7, 2014, the International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund (IUB) filed a putative class action lawsuit against us in the United States District Court for the District of New Jersey alleging that we violated various state antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract with Seratec S.A.R.L. so that Barr Laboratories (“Barr” who at one time held an ANDA for THALOMID ® ) allegedly could not secure its own supply of thalidomide active pharmaceutical ingredient; (b) allegedly refusing to sell samples of our THALOMID ® and REVLIMID ® brand drugs to Mylan Pharmaceuticals, Lannett Company, and Dr. Reddy’s Laboratories so that those companies could conduct the bioequivalence testing needed to submit ANDAs to the FDA for approval to market generic versions of these products; and (c) allegedly bringing unjustified patent infringement lawsuits against Barr and Natco Pharma Limited in order to allegedly delay those companies from obtaining approval for proposed generic versions of THALOMID ® and REVLIMID ® . IUB, on behalf of itself and a putative class of third party payors, is seeking injunctive relief and damages. On February 6, 2015, we filed a motion to dismiss IUB’s complaint. On March 3, 2015, the City of Providence (“Providence”) filed a similar putative class action making similar allegations. Both IUB and Providence, on behalf of themselves and a putative class of third party payors, are seeking injunctive relief and damages. Providence agreed that the decision in the motion to dismiss IUB’s complaint would apply to the identical claims in Providence’s complaint as well. On October 30, 2015, the court denied our motion to dismiss on all grounds. The Court entered an Order on July 6, 2015 scheduling the production of certain discovery for the case through October 1, 2015. A status conference is scheduled for January 5, 2016. Dates for the completion of fact and expert discovery have not been set. We intend to vigorously defend against IUB’s claims. On July 20, 2015, a putative class action lawsuit, Scott v. Receptos, Inc., related to our acquisition of Receptos, was commenced by the filing of a complaint in the Court of Chancery for the State of Delaware, Case No. 11316, against Receptos, members of the Receptos Board, Celgene and Celgene’s wholly-owned subsidiary, Strix Corporation, which is a party to the acquisition agreement. Four other complaints, Cacioppo v. Hasnain and Rosenberg v. Receptos, Inc. (Cases Nos. 11324 and 11325) filed on July 23, and Kadin v. Receptos, Inc., filed on July 27 (Case No. 11337), and Rockaway v. Hasnain (Case No. 11346) filed on July 28, 2015 raise similar putative class claims in the Court of Chancery for the State of Delaware against some or all of Receptos, members of the Receptos Board, Celgene, and Strix Corporation. These complaints generally allege breaches of fiduciary duty by members of the Receptos Board in connection with the Merger Agreement. In the Scott, Rosenberg and Kadin actions, the plaintiffs also allege that Celgene and Strix Corporation aided and abetted the purported breaches of fiduciary duty. On August 17, 2015, all parties to these actions entered into a Memorandum of Understanding (MOU), which sets forth the parties’ agreement in principle for a settlement of the actions. The MOU contemplates that the parties will seek to enter into a stipulation of settlement providing for a global release of claims relating to the acquisition as set forth in the MOU. The claims will not be released until such stipulation of settlement is approved by the Court of Chancery of the State of Delaware. There can be no assurance that the parties will ultimately enter into a stipulation of settlement or that the court will approve such settlement even if the parties were to enter into such stipulation. The settlement did not affect the consideration received by Receptos’ stockholders in connection with the acquisition. As part of the settlement, Receptos agreed to make certain additional disclosures related to the acquisition. Under the America Invents Act (AIA) enacted in 2011, members of the public may seek to challenge an issued patent by petitioning the United States Patent and Trademark Office (USPTO) to institute a post grant review. On April 23, 2015, we were informed that Coalition for Affordable Drugs VI LLC filed several petitions seeking to institute Inter Partes Review (IPRs) challenging the validity of Celgene’s patent US 6,045,501 and US 6,315,720 having claims that cover certain aspects of our REMS program. On October 27, 2015, the USPTO Patent Trial and Appeal Board (PTAB) instituted IPR proceedings relating to these patents. In accordance with the requirements of the AIA, we expect final decisions from the PTAB not later than one year after the institution of the IPRs. Discovery, briefing and oral arguments will be scheduled in the near future. Any patent claim the PTAB determines to be unpatentable is stricken from the challenged patent. Any party may appeal final written decisions of the PTAB to the United States Court of Appeals for the Federal Circuit. We intend to continue to vigorously defend our patent claims.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event In October 2015, we completed the purchase of real property in Summit, New Jersey that includes 12 buildings. The site has approximately 850,000 square feet of administrative office space and 450,000 square feet of R&D space. The purchase of the Summit New Jersey campus together with the construction of a 550,000 square foot addition at our global headquarters will enable us to consolidate our New Jersey operations into our two Summit, New Jersey campuses. We expect to incur restructuring expenses associated with the relocation of operations into the two campuses during 2015 and 2016.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The total consideration for the acquisition of Receptos was $7,626.2 million , consisting of cash and is summarized as follows: Total Consideration Cash paid for outstanding common stock $ 7,311.3 Cash for equity compensation attributable to pre-combination service (1) 314.9 Total consideration $ 7,626.2 (1) $28.6 million for equity compensation attributable to pre-combination service remained payable at September 30, 2015 and will be paid prior to December 31, 2015. The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective preliminary fair values summarized below: Amounts Recognized as of the Acquisition Date (Provisional) Working capital (1) $ 479.2 Current deferred tax assets 238.2 Property, plant and equipment 5.0 In-process research and development product rights 6,842.0 Other non-current assets 7.9 Non-current deferred tax liabilities (2,497.0 ) Total identifiable net assets 5,075.3 Goodwill 2,550.9 Total net assets acquired $ 7,626.2 (1) Includes cash and cash equivalents, available for sale marketable securities, other current assets, accounts payable and other current liabilities. From the Acquisition Date through September 30, 2015, our Consolidated Statements of Operations included expenses of $235.3 million associated with the acquisition and operations of Receptos as follows (1) : Statements of Operations Location Acquisition Date Through September 30, 2015 Research and development $ 21.9 Selling, general and administrative 1.1 Acquisition related (gains) charges and restructuring, net (2) 211.7 Other income (expense), net 0.6 Total $ 235.3
Business Acquisition, Pro Forma Information [Table Text Block]	The following table provides unaudited pro forma financial information for the three- and nine-month periods ended September 30, 2015 and 2014 as if the acquisition of Receptos had occurred on January 1, 2014. Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Total revenue $ 2,334.1 $ 1,985.7 $ 6,692.7 $ 5,590.8 Net income $ 107.3 $ 445.4 $ 1,029.8 $ 952.2 Net income per common share: basic $ 0.14 $ 0.56 $ 1.30 $ 1.19 Net income per common share: diluted $ 0.13 $ 0.53 $ 1.24 $ 1.14

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of earnings per share	Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, (Amounts in millions, except per share) 2015 2014 2015 2014 Net income (loss) $ (34.1 ) $ 508.5 $ 1,041.0 $ 1,386.0 Weighted-average shares: Basic 791.1 799.6 794.3 803.5 Effect of dilutive securities: Options, restricted stock units and other incentives — 33.2 33.4 32.9 Diluted 791.1 832.8 827.7 836.4 Net income (loss) per share: Basic $ (0.04 ) $ 0.64 $ 1.31 $ 1.72 Diluted $ (0.04 ) $ 0.61 $ 1.26 $ 1.66
Gains from premium put options	During the three-month and nine-month periods ended September 30, 2015 and 2014, we recorded losses and gains from put option activity on our Consolidated Statements of Operations in other income (expense), net as follows: Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Gain (loss) from sale of put options $ (18.8 ) $ 3.6 $ (9.9 ) $ 9.9

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Summary of other comprehensive income (loss)	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows: Pension Liability Net Unrealized Gains (Losses) From Marketable Securities Net Unrealized Gains (Losses) From Hedges Foreign Currency Translation Adjustment Total Accumulated Other Comprehensive Income (Loss) Balance December 31, 2014 $ (15.5 ) $ 460.9 $ 519.6 $ (50.2 ) $ 914.8 Other comprehensive income (loss) before reclassifications (7.6 ) (297.8 ) 285.3 (11.9 ) (32.0 ) Amounts reclassified from accumulated other comprehensive income — 7.5 (251.1 ) — (243.6 ) Net current-period other comprehensive income (loss) (7.6 ) (290.3 ) 34.2 (11.9 ) (275.6 ) Balance September 30, 2015 $ (23.1 ) $ 170.6 $ 553.8 $ (62.1 ) $ 639.2 Balance December 31, 2013 $ (6.9 ) $ 137.3 $ (36.0 ) $ (0.4 ) $ 94.0 Other comprehensive income (loss) before reclassifications — 129.6 355.1 (32.5 ) 452.2 Amounts reclassified from accumulated other comprehensive income — 2.7 3.6 — 6.3 Net current-period other comprehensive income (loss) — 132.3 358.7 (32.5 ) 458.5 Balance September 30, 2014 $ (6.9 ) $ 269.6 $ 322.7 $ (32.9 ) $ 552.5
Schedule of gains (losses) reclassified out of accumulated other comprehensive income	Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income Components Affected Line Item in the Consolidated Statements of Operations Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Gains (losses) from cash-flow hedges: Foreign exchange contracts Net product sales $ 92.9 $ 1.3 $ 253.6 $ (1.7 ) Treasury rate lock agreements Interest (expense) (1.1 ) (0.9 ) (2.9 ) (2.6 ) Interest rate swap agreements Interest (expense) (0.4 ) (0.3 ) (1.1 ) (0.5 ) Income tax benefit 0.5 0.5 1.5 1.2 Gains (losses) from available-for-sale marketable securities: Realized income (loss) on sales of marketable securities Interest and investment income, net (10.9 ) (1.2 ) (11.6 ) (4.2 ) Income tax benefit 3.9 0.4 4.1 1.5 Total reclassification, net of tax $ 84.9 $ (0.2 ) $ 243.6 $ (6.3 )

Financial Instruments and Fai27

Financial Instruments and Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Assets and liabilities measured at fair value on recurring basis	•
Roll-forward of fair value of Level 3 instruments (significant unobservable inputs), liabilities	The following table represents a roll-forward of the fair value of Level 3 instruments: Nine-Month Periods Ended September 30, 2015 2014 Liabilities: Balance at beginning of period $ (1,279.0 ) $ (228.5 ) Amounts acquired or issued — (1,060.0 ) Net change in fair value (49.5 ) 17.6 Settlements — 20.0 Transfers in and/or out of Level 3 — — Balance at end of period $ (1,328.5 ) $ (1,250.9 )

Derivative Instruments and He28

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative [Line Items]
Schedule of foreign exchange contracts, statement of financial position	Outstanding foreign currency option contracts entered into to hedge forecasted revenue were as follows at September 30, 2015 and December 31, 2014 : Notional Amount 1 September 30, 2015 December 31, 2014 Foreign currency option contracts designated as hedging activity: Purchased Put $ 524.1 $ 152.6 Written Call $ 562.4 $ 160.9 1 U.S. dollar notional amounts are calculated as the hedged local currency amount multiplied by the strike value of the foreign currency option. The local currency notional amounts of our purchased put and written call that are designated as hedging activities are equal to each other.
Schedule of fair value and balance sheet location of derivative instruments	The following tables summarize the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2015 and December 31, 2014 : September 30, 2015 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 329.5 $ 28.1 Other current liabilities 0.5 1.8 Other non-current assets 321.3 33.3 Interest rate swap agreements Other current assets 23.6 — Other non-current assets 65.1 — Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 39.4 9.1 Other current liabilities — 0.9 Interest rate swap agreements Other current assets 0.7 0.7 Other non-current assets 1.4 0.3 Total $ 781.5 $ 74.2 December 31, 2014 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts (1) Other current assets $ 264.9 $ 44.9 Other current liabilities 0.1 1.7 Other non-current assets 322.3 17.5 Interest rate swap agreements Other current assets 17.9 — Other non-current assets 4.8 0.3 Other non-current liabilities — 3.8 Derivatives not designated as hedging instruments: Foreign exchange contracts (1) Other current assets 39.7 6.0 Other current liabilities 0.1 1.1 Interest rate swap agreements Other current assets 0.1 — Other non-current assets 1.3 — Total $ 651.2 $ 75.3 (1) Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20. The following tables summarize the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2015 and December 31, 2014 : September 30, 2015 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts 1 Other current assets $ 329.5 $ 28.1 Other current liabilities 0.5 1.8 Other non-current assets 321.3 33.3 Interest rate swap agreements Other current assets 23.6 — Other non-current assets 65.1 — Derivatives not designated as hedging instruments: Foreign exchange contracts 1 Other current assets 39.4 9.1 Other current liabilities — 0.9 Interest rate swap agreements Other current assets 0.7 0.7 Other non-current assets 1.4 0.3 Total $ 781.5 $ 74.2 December 31, 2014 Fair Value Instrument Balance Sheet Location Asset Derivatives Liability Derivatives Derivatives designated as hedging instruments: Foreign exchange contracts (1) Other current assets $ 264.9 $ 44.9 Other current liabilities 0.1 1.7 Other non-current assets 322.3 17.5 Interest rate swap agreements Other current assets 17.9 — Other non-current assets 4.8 0.3 Other non-current liabilities — 3.8 Derivatives not designated as hedging instruments: Foreign exchange contracts (1) Other current assets 39.7 6.0 Other current liabilities 0.1 1.1 Interest rate swap agreements Other current assets 0.1 — Other non-current assets 1.3 — Total $ 651.2 $ 75.3 (1) Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.
Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income	During the three-month and nine-month periods ended September 30, 2015 and 2014, we recorded losses and gains from put option activity on our Consolidated Statements of Operations in other income (expense), net as follows: Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Gain (loss) from sale of put options $ (18.8 ) $ 3.6 $ (9.9 ) $ 9.9
Cash flow hedges
Derivative [Line Items]
Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income	The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Operations for the three-month periods ended September 30, 2015 and 2014 : Three-Month Period Ended September 30, 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of (1) Location of Amount of Location of Amount of Foreign exchange contracts $ 10.8 Net product sales $ 92.9 Other income, net $ 14.8 (2 ) Treasury rate lock agreements $ (27.9 ) Interest expense $ (1.1 ) Other income, net $ (0.2 ) (3 ) Interest rate swap agreements $ (50.0 ) Interest expense $ (0.4 ) Other income, net $ 0.3 (3 ) (1) Net gains of $320.3 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. (2) The amount of net gains recognized in income represents $14.7 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $0.1 million in gains related to the ineffective portion of the hedging relationships. (3) The amount of net gain recognized in income relates to the ineffective portion of the hedging relationships. Three-Month Period Ended September 30, 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Location of Amount of Location of Amount of Foreign exchange contracts $ 382.8 Net product sales $ 1.3 Other income, net $ (16.4 ) (1 ) Treasury rate lock agreements $ — Interest expense $ (0.9 ) Other income, net $ — Interest rate swap agreements $ — Interest expense $ (0.3 ) Other income, net $ — (1) The amount of net losses recognized in income represents $18.6 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.2 million in gains related to the ineffective portion of the hedging relationships. The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Operations for the nine-month periods ended September 30, 2015 and 2014 : Nine-Month Period Ended September 30, 2015 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of (1) Location of Amount of Location of Amount of Foreign exchange contracts $ 298.7 Net product sales $ 253.6 Other income, net $ 32.2 (2 ) Treasury rate lock agreements $ (27.9 ) Interest expense $ (2.9 ) Other income, net (0.2 ) (3 ) Interest rate swap agreements $ 6.2 Interest expense $ (1.1 ) Other income, net 0.3 (3 ) (1) Net gains of $320.3 million are expected to be reclassified from Accumulated OCI into income in the next 12 months. (2) The amount of net gains recognized in income represents $35.5 million of gains related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $3.3 million in losses related to the ineffective portion of the hedging relationships. (3) The amount of net gain recognized in income relates to the ineffective portion of the hedging relationships. Nine-Month Period Ended September 30, 2014 (Effective Portion) (Ineffective Portion and Amount Excluded From Effectiveness Testing) Instrument Amount of Location of Amount of Location of Amount of Foreign exchange contracts $ 374.9 Net product sales $ (1.7 ) Other income, net $ (19.2 ) (1 ) Treasury rate lock agreements $ — Interest expense $ (2.6 ) Other income, net $ — Interest rate swap agreements $ (32.4 ) Interest expense $ (0.5 ) Other income, net $ (3.6 ) (2 ) (1) The amount of net losses recognized in income represents $22.1 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.9 million in gains related to the ineffective portion of the hedging relationships. (2) The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships.
Fair value hedges
Derivative [Line Items]
Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income	The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain (Loss) Recognized in Income on Derivative Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, Instrument 2015 2014 2015 2014 Foreign exchange contracts Other income (expense), net $ 14.4 $ 55.4 $ 69.3 $ 44.3 Put options on our common stock Other income (expense), net $ (18.8 ) $ 3.6 $ (9.9 ) $ 9.9 The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Amount of Gain (Loss) Recognized in Income on Derivative Location of Gain (Loss) Recognized in Income on Derivative Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, Instrument 2015 2014 2015 2014 Interest rate swap agreements Interest expense $ 16.2 $ 10.3 $ 45.5 $ 31.2
Foreign currency forward contracts
Derivative [Line Items]
Schedule of notional amount of derivative contracts	Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2015 and December 31, 2014 : Notional Amount Foreign Currency September 30, 2015 December 31, 2014 Australian Dollar $ 38.6 $ 18.8 British Pound 332.6 304.8 Canadian Dollar 84.4 43.7 Euro 3,290.3 3,375.7 Japanese Yen 555.2 541.1 Total $ 4,301.1 $ 4,284.1
Interest rate swap contracts
Derivative [Line Items]
Schedule of notional amount of derivative contracts	The following table summarizes the notional amounts of our outstanding swap contracts at September 30, 2015 and December 31, 2014 : Notional Amount September 30, 2015 December 31, 2014 Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes: 2.450% senior notes due 2015 $ 300.0 $ 300.0 1.900% senior notes due 2017 300.0 300.0 2.300% senior notes due 2018 200.0 200.0 2.250% senior notes due 2019 500.0 500.0 3.950% senior notes due 2020 500.0 500.0 3.250% senior notes due 2022 1,000.0 750.0 4.000% senior notes due 2023 700.0 150.0 3.625% senior notes due 2024 100.0 — Total $ 3,600.0 $ 2,700.0

Cash, Cash Equivalents and Ma29

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables)	9 Months Ended
	Sep. 30, 2015
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule of available-for-sale securities by major security type and class	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at September 30, 2015 and December 31, 2014 were as follows: September 30, 2015 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 92.8 $ — $ — $ 92.8 U.S. government-sponsored agency MBS 34.0 — (0.2 ) 33.8 Corporate debt - global 213.4 0.2 (1.0 ) 212.6 Asset backed securities 38.6 — — 38.6 Marketable equity securities 820.3 365.8 (74.8 ) 1,111.3 Total available-for-sale marketable securities $ 1,199.1 $ 366.0 $ (76.0 ) $ 1,489.1 December 31, 2014 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Estimated Fair Value U.S. Treasury securities $ 1,044.7 $ 0.3 $ (0.8 ) $ 1,044.2 U.S. government-sponsored agency securities 145.1 0.1 (0.1 ) 145.1 U.S. government-sponsored agency MBS 531.1 1.0 (2.7 ) 529.4 Non-U.S. government, agency and Supranational securities 32.4 — (0.1 ) 32.3 Corporate debt - global 446.3 0.6 (1.2 ) 445.7 Asset backed securities 177.3 — (0.2 ) 177.1 Marketable equity securities 335.2 716.3 (0.2 ) 1,051.3 Total available-for-sale marketable securities $ 2,712.1 $ 718.3 $ (5.3 ) $ 3,425.1
Schedule of duration periods of available-for-sale debt securities	Duration periods of available-for-sale debt securities at September 30, 2015 were as follows: Amortized Cost Fair Value Duration of one year or less $ 68.1 $ 67.9 Duration of one through three years 292.6 291.9 Duration of three through five years 18.1 18.0 Total $ 378.8 $ 377.8

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Summary of inventories by major category	September 30, 2015 and December 31, 2014 are summarized by major category as follows: September 30, 2015 December 31, 2014 Raw materials $ 109.8 $ 200.0 Work in process 131.4 101.5 Finished goods 179.7 91.6 Total $ 420.9 $ 393.1

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets by category	Intangible assets outstanding as of September 30, 2015 and December 31, 2014 are summarized as follows: September 30, 2015 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,387.1 ) $ 2,018.8 Technology 333.7 (170.8 ) 162.9 Licenses 66.7 (21.2 ) 45.5 Other 44.0 (26.1 ) 17.9 3,850.3 (1,605.2 ) 2,245.1 Non-amortized intangible assets: Acquired IPR&D product rights 8,470.7 — 8,470.7 Total intangible assets $ 12,321.0 $ (1,605.2 ) $ 10,715.8 December 31, 2014 Gross Carrying Value Accumulated Amortization Intangible Assets, Net Amortizable intangible assets: Acquired developed product rights $ 3,405.9 $ (1,234.1 ) $ 2,171.8 Technology 333.7 (135.1 ) 198.6 Licenses 67.0 (18.1 ) 48.9 Other 42.5 (22.9 ) 19.6 3,849.1 (1,410.2 ) 2,438.9 Non-amortized intangible assets: Acquired IPR&D product rights 1,628.7 — 1,628.7 Total intangible assets $ 5,477.8 $ (1,410.2 ) $ 4,067.6

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of short-term debt	The carrying value of short-term borrowings and current portion of long-term debt outstanding at September 30, 2015 and December 31, 2014 includes: September 30, 2015 December 31, 2014 Commercial paper $ 699.4 $ 99.6 2.450% senior notes due 2015 500.3 506.3 Total $ 1,199.7 $ 605.9
Carrying values of the senior notes	Summarized below are the carrying values of our senior notes at September 30, 2015 and December 31, 2014 : September 30, 2015 December 31, 2014 1.900% senior notes due 2017 $ 503.0 $ 501.0 2.125% senior notes due 2018 999.9 — 2.300% senior notes due 2018 403.8 401.2 2.250% senior notes due 2019 511.3 502.5 2.875% senior notes due 2020 1,497.4 — 3.950% senior notes due 2020 514.6 502.8 3.250% senior notes due 2022 1,032.3 1,010.2 3.550% senior notes due 2022 997.3 — 4.000% senior notes due 2023 722.2 708.5 3.625% senior notes due 2024 1,003.4 996.8 3.875% senior notes due 2025 2,476.1 — 5.700% senior notes due 2040 249.6 249.5 5.250% senior notes due 2043 396.7 396.7 4.625% senior notes due 2044 996.5 996.5 5.000% senior notes due 2045 1,993.8 — Total long-term debt $ 14,297.9 $ 6,265.7

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of share-based compensation expense	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations for the three- and nine-month periods ended September 30, 2015 and 2014 : Three-Month Periods Ended September 30, Nine-Month Periods Ended September 30, 2015 2014 2015 2014 Cost of goods sold (excluding amortization of acquired intangible assets) $ 8.5 $ 6.8 $ 23.3 $ 18.8 Research and development 65.2 48.4 185.0 141.2 Selling, general and administrative 76.2 56.2 218.1 159.2 Total share-based compensation expense 149.9 111.4 426.4 319.2 Tax benefit related to share-based compensation expense 42.8 31.4 124.0 92.4 Reduction in income $ 107.1 $ 80.0 $ 302.4 $ 226.8
Summary of activity for stock options, RSUs and PSUs	The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2015 (in millions unless otherwise noted): Stock Options Restricted Stock Units Performance- (in thousands) Outstanding at December 31, 2014 77.2 9.4 133 Changes during the Year: Granted 8.7 1.8 211 Exercised / Released (9.0 ) (3.0 ) — Forfeited (1.3 ) (0.3 ) (7 ) Outstanding at September 30, 2015 75.6 7.9 337
Schedule of unvested awards compensation cost not yet recognized and weighted-average periods for recognition	Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2015 were as follows (dollars in millions): Stock Options Restricted Stock Units Performance- Based Restricted Stock Units Unrecognized compensation cost $ 613.4 $ 304.3 $ 20.4 Expected weighted-average period in years of compensation cost to be recognized 2.0 1.3 1.7

Collaboration Agreements (Table

Collaboration Agreements (Tables)	9 Months Ended
	Sep. 30, 2015
Collaboration Agreements [Abstract]
Schedule of Collaboration Agreements	A financial summary of certain period activity related to our collaboration agreements is presented below 1,2 : Three-Month Periods Ended September 30, Research and Development Expense Upfront Fees Milestones Extension/Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Acetylon 2015 $— $— $— $5.4 $— 2014 — — — 4.3 — bluebird 2015 — — — 2.1 — 2014 — — — 0.1 — Epizyme 2015 — — 10.0 — — 2014 — — — — — Juno 2015 575.1 — — — 424.9 Nurix 2015 149.8 — — — 17.0 Sutro 2015 — — — 1.4 — 2014 72.6 — — 0.1 11.9 Other Collaboration Arrangements 2015 26.9 — — — — 2014 6.0 6.8 — 0.4 27.0 Nine-Month Periods Ended September 30, Research and Development Expense Upfront Fees Milestones Extension/Termination of Agreements Amortization of Prepaid Research and Development Equity Investments Made During Period Acceleron 2015 $— $— $— $— $— 2014 — — — — 52.4 Acetylon 2015 — — — 14.6 — 2014 — — — 11.4 — Agios 2015 9.0 — — — — 2014 — — — — 13.0 AstraZeneca 2015 450.0 — — — — bluebird 2015 — — — 2.8 — 2014 — — — 0.1 — Epizyme 2015 — — 10.0 — — 2014 — — — — 9.9 FORMA 2015 39.0 — — — — 2014 225.0 — — 0.1 — Juno 2015 575.1 — — — 424.9 Lycera 2015 69.5 — — — 10.0 MorphoSys 2015 — — 8.1 — — 2014 — — — — — NantBioScience (3) 2015 — — — — — 2014 50.0 — — — 90.0 Nurix 2015 149.8 — — — 17.0 Sutro 2015 — — — 3.4 — 2014 72.6 — — 0.2 11.9 Other Collaboration Arrangements 2015 47.9 8.0 — 0.9 50.0 2014 54.0 7.3 — 6.9 47.9 A financial summary of the period-end balances related to our collaboration agreements is presented below: Balances as of: Intangible Asset Balance Equity Investment Balance Percentage of Outstanding Equity Acceleron September 30, 2015 $— $114.8 14% December 31, 2014 — 179.7 14% Acetylon September 30, 2015 5.8 25.0 11% December 31, 2014 20.4 25.0 10% Agios September 30, 2015 1.0 370.1 13% December 31, 2014 — 587.4 14% bluebird September 30, 2015 22.3 N/A N/A December 31, 2014 0.1 N/A N/A Epizyme September 30, 2015 — 47.3 8% December 31, 2014 — 69.3 11% FORMA September 30, 2015 0.1 N/A N/A December 31, 2014 0.1 N/A N/A Juno September 30, 2015 — 371.8 9% Lycera September 30, 2015 3.0 10.0 8% MorphoSys September 30, 2015 — 53.1 3% December 31, 2014 — 73.9 3% NantBioScience September 30, 2015 — 90.0 13% December 31, 2014 — 90.0 14% Nurix September 30, 2015 0.2 17.0 13% Sutro September 30, 2015 24.4 17.6 15% December 31, 2014 12.8 17.6 15% Other Collaboration Arrangements September 30, 2015 22.1 130.1 N/A December 31, 2014 34.4 90.8 N/A 1 Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2014 Annual Report on Form 10-K if there has been new significant activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements. 2 In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us. 3 $25.0 million of expense related to the settlement of contingent matching contributions was also recognized at the 2014 inception of the collaboration agreement with NantBioScience and included in Selling, General and Administrative expense.

Nature of Business and Basis 35

Nature of Business and Basis of Presentation (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Maximum equity ownership percentage, investments	50.00%

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Millions	Oct. 19, 2015	Aug. 27, 2015	Aug. 26, 2015	Apr. 23, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Total costs and expenses						$ 2,254.5	$ 1,335.6		$ 5,338.3	$ 3,817.6
Payments for acquisition of business									7,579.3	710
Total share-based compensation expense						149.9	$ 111.4		426.4	$ 319.2
Nogra
Business Acquisition [Line Items]
Payments for acquisition of business				$ 710
Potential milestone payment				815	$ 1,213	1,213			1,213
Potential tiered sales milestones				500
Global annual sales				4,000
Nogra | Other current liabilities
Business Acquisition [Line Items]
Contingent consideration					25	25			25
Nogra | Other non-current liabilities
Business Acquisition [Line Items]
Contingent consideration					1,188	$ 1,188			$ 1,188
Nogra | Maximum
Business Acquisition [Line Items]
Global annual sales				$ 1,050
Receptos
Business Acquisition [Line Items]
Total costs and expenses			$ 19.9		$ 235.3
Total consideration		$ 7,626.2
Cash paid for outstanding common stock		7,311
Cash for equity compensation attributable to pre-combination service(1)		$ 315
Scenario, Forecast | Receptos
Business Acquisition [Line Items]
Total share-based compensation expense								$ 197
Subsequent Event | Quanticel Pharmaceuticals
Business Acquisition [Line Items]
Payments for acquisition of business	$ 100
Subsequent Event | Development milestone | Quanticel Pharmaceuticals
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset	$ 385

Acquisitions (Total Considerati

Acquisitions (Total Consideration) (Details) - Receptos $ in Millions	Aug. 27, 2015USD ($)
Business Acquisition [Line Items]
Cash paid for outstanding common stock	$ 7,311
Cash for equity compensation attributable to pre-combination service(1)	315
Total consideration	7,626.2
Equity compensation attributable to per-combination service, payable	$ 28.6

Acquisitions (Purchase Price Al

Acquisitions (Purchase Price Allocation) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Aug. 27, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 4,742		$ 2,191.2
Receptos
Business Acquisition [Line Items]
Working capital (1)		$ 479.2
Current deferred tax assets		238.2
Property, plant and equipment		5
In-process research and development product rights		6,842
Other non-current assets		7.9
Non-current deferred tax liabilities		(2,497)
Total identifiable net assets		5,075.3
Goodwill		2,550.9
Total net assets acquired		$ 7,626.2

Acquisitions (Statement of Oper

Acquisitions (Statement of Operations Location) (Details) - USD ($) $ in Millions	Aug. 26, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Research and development			$ 1,304.5	$ 675.1	$ 2,920.5	$ 1,845.7
Selling, general and administrative			550.3	497.6	1,696.3	1,483.5
Acquisition related charges and restructuring, net			226.2	1.5	215.9	11
Other income (expense), net			(19.6)	(22.5)	83.2	(46.9)
Total costs and expenses			$ 2,254.5	$ 1,335.6	$ 5,338.3	$ 3,817.6
Receptos
Business Acquisition [Line Items]
Research and development		$ 21.9
Selling, general and administrative		1.1
Acquisition related charges and restructuring, net		211.7
Other income (expense), net		0.6
Total costs and expenses	$ 19.9	$ 235.3

Acquisitions (Pro Forma) (Detai

Acquisitions (Pro Forma) (Details) - Receptos - USD ($) $ / shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Pro forma revenue	$ 2,334.1	$ 1,985.7	$ 6,692.7	$ 5,590.8
Business Acquisition, Pro Forma Net Income (Loss)	$ 107.3	$ 445.4	$ 1,029.8	$ 952.2
Pro forma earnings per share, basic	$ 140	$ 560	$ 1,300	$ 1,190
Pro forma earnings per share, diluted	$ 130	$ 530	$ 1,240	$ 1,140

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	32,500,000	13,700,000	11,600,000	17,900,000
Authorized amount, increase					$ 4,000,000,000
Aggregate authorized amount					$ 17,500,000,000
Shares repurchased under share repurchase program (in shares)	7,100,000		24,500,000
Shares repurchased under share repurchase program	$ 815,400,000		$ 2,849,000,000
Remaining authorized repurchase amount under stock purchase program	$ 4,297,000,000		$ 4,297,000,000
Purchased Put
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Put options outstanding	0		0

Earnings Per Share (Schedule of

Earnings Per Share (Schedule of Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net income	$ (34.1)	$ 508.5	$ 1,041	$ 1,386
Weighted-average shares:
Basic (in shares)	791.1	799.6	794.3	803.5
Effect of dilutive securities:
Options, restricted stock units and other incentives	0	33.2	33.4	32.9
Diluted (in shares)	791.1	832.8	827.7	836.4
Net income (loss) per share:
Basic (in dollars per share)	$ (0.04)	$ 0.64	$ 1.31	$ 1.72
Diluted (in dollars per share)	$ (0.04)	$ 0.61	$ 1.26	$ 1.66

Earnings Per Share (Gains from

Earnings Per Share (Gains from Premium Put Options) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other income (expense) | Purchased Put
Derivative Instruments, Gain (Loss) [Line Items]
Gain on put option premium	$ (18.8)	$ 3.6	$ (9.9)	$ 9.9

Accumulated Other Comprehensi44

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			$ 914.8	$ 94
Other comprehensive income (loss) before reclassifications			(32)	452.2
Amounts reclassified from accumulated other comprehensive income			(243.6)	6.3
Total other comprehensive income (loss)	$ (418.9)	$ 388.8	(275.6)	458.5
Balance at the end of the period	639.2	552.5	639.2	552.5
Pension Liability
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			(15.5)	(6.9)
Other comprehensive income (loss) before reclassifications			(7.6)	0
Amounts reclassified from accumulated other comprehensive income			0	0
Total other comprehensive income (loss)			(7.6)	0
Balance at the end of the period	(23.1)	(6.9)	(23.1)	(6.9)
Net Unrealized Gains (Losses) From Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			460.9	137.3
Other comprehensive income (loss) before reclassifications			(297.8)	129.6
Amounts reclassified from accumulated other comprehensive income			7.5	2.7
Total other comprehensive income (loss)			(290.3)	132.3
Balance at the end of the period	170.6	269.6	170.6	269.6
Net Unrealized Gains (Losses) From Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			519.6	(36)
Other comprehensive income (loss) before reclassifications			285.3	355.1
Amounts reclassified from accumulated other comprehensive income			(251.1)	3.6
Total other comprehensive income (loss)			34.2	358.7
Balance at the end of the period	553.8	322.7	553.8	322.7
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at the beginning of the period			(50.2)	(0.4)
Other comprehensive income (loss) before reclassifications			(11.9)	(32.5)
Amounts reclassified from accumulated other comprehensive income			0	0
Total other comprehensive income (loss)			(11.9)	(32.5)
Balance at the end of the period	$ (62.1)	$ (32.9)	$ (62.1)	$ (32.9)

Accumulated Other Comprehensi45

Accumulated Other Comprehensive Income (Loss) (Reclassification of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other Comprehensive Income (Loss)
Net product sales	$ 2,312.6	$ 1,956.8	$ 6,621.9	$ 5,508.9
Interest (expense)	(88.5)	(53.5)	(186)	(124.4)
Income tax benefit	(14.2)	(69)	(237)	(230.6)
Interest and investment income, net	8.6	6.9	26.4	20.6
Net income	(34.1)	508.5	1,041	1,386
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income
Other Comprehensive Income (Loss)
Net income	84.9	(0.2)	243.6	(6.3)
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Gains (losses) from cash-flow hedges: | Foreign exchange contracts
Other Comprehensive Income (Loss)
Net product sales	92.9	1.3	253.6	(1.7)
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Gains (losses) from cash-flow hedges: | Treasury rate lock agreements
Other Comprehensive Income (Loss)
Interest (expense)	(1.1)	(0.9)	(2.9)	(2.6)
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Gains (losses) from cash-flow hedges: | Interest rate swap agreements
Other Comprehensive Income (Loss)
Interest (expense)	(0.4)	(0.3)	(1.1)	(0.5)
Income tax benefit	0.5	0.5	1.5	1.2
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income | Gains (losses) from available-for-sale marketable securities:
Other Comprehensive Income (Loss)
Income tax benefit	3.9	0.4	4.1	1.5
Interest and investment income, net	$ (10.9)	$ (1.2)	$ (11.6)	$ (4.2)

Financial Instruments and Fai46

Financial Instruments and Fair Value Measurement (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Business Acquisition [Line Items]
Net increase during period	$ 49.5
Nogra
Business Acquisition [Line Items]
Potential milestone payment	1,865
Maximum | Gloucester Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Potential milestone payment	120
Maximum | Avila
Business Acquisition [Line Items]
Potential milestone payment	$ 555

Financial Instruments and Fai47

Financial Instruments and Fair Value Measurement (Measurement Inputs) (Details) - Recurring basis - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Quoted Price in Active Markets for Identical Assets (Level 1)
Assets:
Purchased currency options	$ 1,111.3	$ 1,051.3
Interest rate swaps	0	0
Purchased currency options	0	0
Interest rate swaps	0	0
Total assets	1,111.3	1,051.3
Liabilities:
Contingent value rights	(69.7)	(136.3)
Written currency options	0	0
Other acquisition related contingent consideration	0	0
Total liabilities	(69.7)	(136.3)
Significant Other Observable Inputs (Level 2)
Assets:
Purchased currency options	377.8	2,373.8
Interest rate swaps	599.9	550.7
Purchased currency options	36.3	9.8
Interest rate swaps	89.8	20
Total assets	1,103.8	2,954.3
Liabilities:
Contingent value rights	0	0
Written currency options	(18.7)	(4.6)
Other acquisition related contingent consideration	0	0
Total liabilities	(18.7)	(4.6)
Significant Unobservable Inputs (Level 3)
Assets:
Purchased currency options	0	0
Interest rate swaps	0	0
Purchased currency options	0	0
Interest rate swaps	0	0
Total assets	0	0
Liabilities:
Contingent value rights	0	0
Written currency options	0	0
Other acquisition related contingent consideration	(1,328.5)	(1,279)
Total liabilities	(1,328.5)	(1,279)
Fair Value
Assets:
Purchased currency options	1,489.1	3,425.1
Interest rate swaps	599.9	550.7
Purchased currency options	36.3	9.8
Interest rate swaps	89.8	20
Total assets	2,215.1	4,005.6
Liabilities:
Contingent value rights	(69.7)	(136.3)
Written currency options	(18.7)	(4.6)
Other acquisition related contingent consideration	(1,328.5)	(1,279)
Total liabilities	$ (1,416.9)	$ (1,419.9)

Financial Instruments and Fai48

Financial Instruments and Fair Value Measurement (Level 3 Fair Value Roll-Forward) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ (1,279)	$ (228.5)
Amounts acquired or issued	0	(1,060)
Net change in fair value	(49.5)	17.6
Settlements	0	20
Transfers in and/or out of Level 3	0	0
Balance at end of period	$ (1,328.5)	$ (1,250.9)

Derivative Instruments and He49

Derivative Instruments and Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Designated as hedging instruments
Derivative [Line Items]
Gains (losses) expected to be reclassified from accumulated OCI into operations in the next 12 months		$ 320.3		$ 320.3
Foreign currency forward contracts
Derivative [Line Items]
Period to settlement dates of derivatives is within this period				3 years
Foreign currency forward contracts | Designated as hedging instruments
Derivative [Line Items]
Period to settlement dates of derivatives is within this period				36 months		36 months
Foreign currency forward contracts | Not designated as hedging instruments
Derivative [Line Items]
Notional amount		831.8		$ 831.8		$ 835.5
Interest rate swap contracts | Designated as hedging instruments
Derivative [Line Items]
Proceeds from settlement of interest rate swap contracts				7.7	$ 15.3
Cash flow hedges | Foreign currency forward contracts | Designated as hedging instruments
Derivative [Line Items]
Notional amount		4,301.1		4,301.1		$ 4,284.1
Cash flow hedges | Treasury Lock Maturing in Year Ten [Member] | Designated as hedging instruments
Derivative [Line Items]
Remaining maturity	10 years
Cash flow hedges | Interest rate swap contracts | Designated as hedging instruments
Derivative [Line Items]
Notional amount		1,300		1,300
Cash flow hedges | Treasury rate lock | Designated as hedging instruments
Derivative [Line Items]
Notional amount		1,600		1,600
Cash flow hedges | Interest Rate Swaps and Treasury Locks | Designated as hedging instruments
Derivative [Line Items]
Derivative Liability, Notional Amount		21.6
Other income, net | Cash flow hedges | Foreign currency forward contracts | Designated as hedging instruments
Derivative [Line Items]
Gains (losses) related to amounts excluded from assessment of hedge effectiveness		14.7	$ (18.6)	35.5	(22.1)
Gain on cash flow hedge ineffectiveness		$ 0.1
Gains (losses) related to the ineffective portion of the hedging relationships			$ 2.2	$ (3.3)	$ 2.9

Derivative Instruments and He50

Derivative Instruments and Hedging Activities (Foreign Currency Forward Contracts) (Details) - Cash flow hedges - Foreign currency forward contracts - Designated as hedging instruments - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	$ 4,301.1	$ 4,284.1
Australian Dollar
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	38.6	18.8
Australian Dollar
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	332.6	304.8
Canadian Dollar
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	84.4	43.7
Euro
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	3,290.3	3,375.7
Japanese Yen
Derivative Instruments, Gain (Loss) [Line Items]
Notional amount	$ 555.2	$ 541.1

Derivative Instruments and He51

Derivative Instruments and Hedging Activities (Foreign Currency Option Contracts) (Details) - Foreign currency forward contracts - Designated as hedging instruments - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Long | Purchased Put
Derivative [Line Items]
Notional amount	$ 524.1	$ 152.6
Short | Written Call
Derivative [Line Items]
Notional amount	$ 562.4	$ 160.9

Derivative Instruments and He52

Derivative Instruments and Hedging Activities (Forward Starting Interest Rate Swaps) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
2.450% senior notes due 2015
Derivative [Line Items]
Interest rate (as a percentage)	2.45%
1.900% senior notes due 2017
Derivative [Line Items]
Interest rate (as a percentage)	1.90%
3.950% senior notes due 2020
Derivative [Line Items]
Interest rate (as a percentage)	3.95%
3.250% senior notes due 2022
Derivative [Line Items]
Interest rate (as a percentage)	3.25%
4.000% senior notes due 2023
Derivative [Line Items]
Interest rate (as a percentage)	4.00%
Senior notes | 2.450% senior notes due 2015
Derivative [Line Items]
Interest rate (as a percentage)	2.45%
Senior notes | 1.900% senior notes due 2017
Derivative [Line Items]
Interest rate (as a percentage)	1.90%
Senior notes | 2.300% senior notes due 2018
Derivative [Line Items]
Interest rate (as a percentage)	2.30%
Senior notes | 2.250% senior notes due 2019
Derivative [Line Items]
Interest rate (as a percentage)	2.25%
Senior notes | 3.950% senior notes due 2020
Derivative [Line Items]
Interest rate (as a percentage)	3.95%
Senior notes | 3.250% senior notes due 2022
Derivative [Line Items]
Interest rate (as a percentage)	3.25%
Senior notes | 4.000% senior notes due 2023
Derivative [Line Items]
Interest rate (as a percentage)	4.00%
Senior notes | 3.630% senior notes due 2024
Derivative [Line Items]
Interest rate (as a percentage)	3.625%
Fair value hedges | Designated as hedging instruments | Interest rate swap contracts
Derivative [Line Items]
Notional amount	$ 3,600	$ 2,700
Fair value hedges | Senior notes | Designated as hedging instruments | 2.450% senior notes due 2015 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	300	300
Fair value hedges | Senior notes | Designated as hedging instruments | 1.900% senior notes due 2017 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	300	300
Fair value hedges | Senior notes | Designated as hedging instruments | 2.300% senior notes due 2018 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	200	200
Fair value hedges | Senior notes | Designated as hedging instruments | 2.250% senior notes due 2019 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	500	500
Fair value hedges | Senior notes | Designated as hedging instruments | 3.950% senior notes due 2020 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	500	500
Fair value hedges | Senior notes | Designated as hedging instruments | 3.250% senior notes due 2022 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	1,000	750
Fair value hedges | Senior notes | Designated as hedging instruments | 4.000% senior notes due 2023 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	700	150
Fair value hedges | Senior notes | Designated as hedging instruments | 3.630% senior notes due 2024 | Interest rate swap contracts
Derivative [Line Items]
Notional amount	$ 100	$ 0

Derivative Instruments and He53

Derivative Instruments and Hedging Activities (Fair Value and Presentation in the Balance Sheet) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	$ 781.5	$ 651.2
Derivative liability, fair value, gross asset	74.2	75.3
Foreign currency forward contracts | Designated as hedging instruments | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	329.5	264.9
Derivative liability, fair value, gross asset	28.1	44.9
Foreign currency forward contracts | Designated as hedging instruments | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross liability	0.5	0.1
Derivative liability, fair value, gross liability	1.8	1.7
Foreign currency forward contracts | Designated as hedging instruments | Other non-current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	321.3	322.3
Derivative liability, fair value, gross asset	33.3	17.5
Interest rate swap contracts | Designated as hedging instruments | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	23.6	17.9
Derivative liability, fair value, gross asset	0	0
Interest rate swap contracts | Designated as hedging instruments | Other non-current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	65.1	4.8
Derivative liability, fair value, gross asset	0	0.3
Interest rate swap contracts | Designated as hedging instruments | Other non-current liabilities
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross liability		0
Derivative liability, fair value, gross liability		3.8
Interest rate swap contracts | Not designated as hedging instruments | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	0.7	0.1
Derivative liability, fair value, gross asset	0.7	0
Interest rate swap contracts | Not designated as hedging instruments | Other non-current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	1.4	1.3
Derivative liability, fair value, gross asset	0.3	0
Foreign exchange contracts | Not designated as hedging instruments | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross asset	39.4	39.7
Derivative liability, fair value, gross asset	9.1	6
Foreign exchange contracts | Not designated as hedging instruments | Other current liabilities
Derivatives, Fair Value [Line Items]
Derivative asset, fair value, gross liability	0	0.1
Derivative liability, fair value, gross liability	$ 0.9	$ 1.1

Derivative Instruments and He54

Derivative Instruments and Hedging Activities (Schedule of Impacts on Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income			$ 249.6	$ (4.8)
Foreign currency forward contracts | Other income, net | Not designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in OCI on Derivative(1)	$ 14.4	$ 55.4	69.3	44.3
Treasury rate lock | Other income, net | Not designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in OCI on Derivative(1)	(18.8)	3.6	(9.9)	9.9
Fair value hedges | Interest rate swap agreements | Interest expense | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in Income on Derivative	16.2	10.3	45.5	31.2
Cash flow hedges | Foreign currency forward contracts | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in OCI on Derivative(1)	10.8	382.8	298.7	374.9
Cash flow hedges | Foreign currency forward contracts | Net product sales | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income	92.9	1.3	253.6	(1.7)
Cash flow hedges | Foreign currency forward contracts | Other income, net | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in Income on Derivative	14.8	(16.4)	32.2	(19.2)
Cash flow hedges | Treasury rate lock | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in OCI on Derivative(1)	(27.9)	0	(27.9)	0
Cash flow hedges | Treasury rate lock | Interest expense | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income	(1.1)	(0.9)	(2.9)	(2.6)
Cash flow hedges | Treasury rate lock | Other income, net | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in Income on Derivative	(0.2)		(0.2)
Cash flow hedges | Interest rate swap agreements | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in OCI on Derivative(1)	(50)	0	6.2	(32.4)
Cash flow hedges | Interest rate swap agreements | Interest expense | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income	(0.4)	(0.3)	(1.1)	(0.5)
Cash flow hedges | Interest rate swap agreements | Other income, net | Designated as hedging instruments
Derivative [Line Items]
Amount of Gain/(Loss) Recognized in Income on Derivative	$ 0.3	$ 0	$ 0.3	$ (3.6)

Cash, Cash Equivalents and Ma55

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Money market funds, at carrying value	$ 2,101	$ 2,251

Cash, Cash Equivalents and Ma56

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Schedule of Available-for-Sale Reconcilation) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 1,199.1	$ 2,712.1
Gross Unrealized Gain	366	718.3
Gross Unrealized Loss	(76)	(5.3)
Estimated Fair Value	1,489.1	3,425.1
U.S. Treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	92.8	1,044.7
Gross Unrealized Gain	0	0.3
Gross Unrealized Loss	0	(0.8)
Estimated Fair Value	92.8	1,044.2
U.S. government-sponsored agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		145.1
Gross Unrealized Gain		0.1
Gross Unrealized Loss		(0.1)
Estimated Fair Value		145.1
U.S. government-sponsored agency MBS
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	34	531.1
Gross Unrealized Gain	0	1
Gross Unrealized Loss	(0.2)	(2.7)
Estimated Fair Value	33.8	529.4
Non-U.S. government, agency and Supranational securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		32.4
Gross Unrealized Gain		0
Gross Unrealized Loss		(0.1)
Estimated Fair Value		32.3
Corporate debt - global
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	213.4	446.3
Gross Unrealized Gain	0.2	0.6
Gross Unrealized Loss	(1)	(1.2)
Estimated Fair Value	212.6	445.7
Asset backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	38.6	177.3
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	(0.2)
Estimated Fair Value	38.6	177.1
Marketable equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	820.3	335.2
Gross Unrealized Gain	365.8	716.3
Gross Unrealized Loss	(74.8)	(0.2)
Estimated Fair Value	$ 1,111.3	$ 1,051.3

Cash, Cash Equivalents and Ma57

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Duration Periods) (Details) $ in Millions	Sep. 30, 2015USD ($)
Amortized Cost
Duration of one year or less	$ 68.1
Duration of one through three years	292.6
Duration of three through five years	18.1
Total	378.8
Fair Value
Duration of one year or less	67.9
Duration of one through three years	291.9
Duration of three through five years	18
Total	$ 377.8

Inventory (Details)

Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 109.8	$ 200
Work in process	131.4	101.5
Finished goods	179.7	91.6
Total	$ 420.9	$ 393.1

Intangible Assets and Goodwil59

Intangible Assets and Goodwill (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Aug. 27, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible assets gross excluding goodwill, increase			$ 6,843
Weighted average life			10 years 6 months
Amortization of acquired intangible assets	$ 65	$ 65	$ 195	$ 198.8
Increase to goodwill	2,550.8		2,550.8
Goodwill	$ 4,742		4,742			$ 2,191.2
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortization			163.7
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortization			$ 306.5
Receptos
Finite-Lived Intangible Assets [Line Items]
In-process research and development product rights					$ 6,842
Goodwill					$ 2,550.9

Intangible Assets and Goodwil60

Intangible Assets and Goodwill (Summary of Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Intangible Assets By Category
Gross Carrying Value	$ 3,850.3	$ 3,849.1
Accumulated Amortization	(1,605.2)	(1,410.2)
Intangible Assets, Net	2,245.1	2,438.9
Total intangible assets
Gross Carrying Value	12,321	5,477.8
Intangible Assets, Net	10,715.8	4,067.6
Acquired developed product rights
Intangible Assets By Category
Gross Carrying Value	3,405.9	3,405.9
Accumulated Amortization	(1,387.1)	(1,234.1)
Intangible Assets, Net	2,018.8	2,171.8
Technology
Intangible Assets By Category
Gross Carrying Value	333.7	333.7
Accumulated Amortization	(170.8)	(135.1)
Intangible Assets, Net	162.9	198.6
Licenses
Intangible Assets By Category
Gross Carrying Value	66.7	67
Accumulated Amortization	(21.2)	(18.1)
Intangible Assets, Net	45.5	48.9
Other
Intangible Assets By Category
Gross Carrying Value	44	42.5
Accumulated Amortization	(26.1)	(22.9)
Intangible Assets, Net	17.9	19.6
Acquired IPR&D product rights
Intangible Assets By Category
Accumulated Amortization	0	0
Non-amortized intangible assets:
Carrying value	$ 8,470.7	$ 1,628.7

Debt (Narrative) (Details)

Debt (Narrative) (Details)	Aug. 31, 2015USD ($)	Sep. 30, 2015USD ($)Time_Per_Annum	Oct. 31, 2015USD ($)	Oct. 01, 2015USD ($)	Dec. 31, 2014USD ($)	Apr. 30, 2013USD ($)
Debt
Commercial paper		$ 699,400,000			$ 99,600,000
Commercial paper, maximum		1,750,000,000		$ 2,750,000,000
Treasury rate lock agreements
Debt
Losses recorded to AOCI		69,700,000
Interest rate swap contracts | Designated as hedging instruments
Debt
Gains recorded as reduction of debt		34,800,000			38,600,000
Gain on settlement of contract		6,000,000
Level 2
Debt
Senior notes, fair value		14,847,000,000
Commercial paper
Debt
Commercial paper		$ 699,400,000			$ 99,600,000
Effective interest rate		0.50%
Senior unsecured credit facility
Debt
Maximum borrowing capacity		$ 1,750,000,000
Senior notes
Debt
Face amount	$ 8,000,000,000
Unamortized debt issuance expense	$ 50,000,000
2.125% senior notes due 2018
Debt
Debt instrument, redemption price, percentage	120000000.00%
Face amount	$ 1,000,000,000
Interest rate (as a percentage)	2.125%
Debt Instrument, Issuance Price as Percentage of Par Value	99.994%
2.875% senior notes due 2020
Debt
Debt instrument, redemption price, percentage	120000000.00%
Face amount	$ 1,500,000,000
Interest rate (as a percentage)	2.875%
Debt Instrument, Issuance Price as Percentage of Par Value	99.819%
3.550% senior notes due 2022
Debt
Debt instrument, redemption price, percentage	125000000.00%
Face amount	$ 1,000,000,000
Interest rate (as a percentage)	3.55%
Debt Instrument, Issuance Price as Percentage of Par Value	99.729%
3.875% senior notes due 2025
Debt
Debt instrument, redemption price, percentage	130000000.00%
Face amount	$ 2,500,000,000
Interest rate (as a percentage)	3.875%
Debt Instrument, Issuance Price as Percentage of Par Value	99.034%
5.000% senior notes due 2045
Debt
Debt instrument, redemption price, percentage	135000000.00%
Face amount	$ 2,000,000,000
Interest rate (as a percentage)	5.00%
Debt Instrument, Issuance Price as Percentage of Par Value	99.691%
Revolving credit facility
Debt
Maximum borrowing capacity						$ 1,500,000,000
Maximum number of times company has right to increase credit facility | Time_Per_Annum		1
Maximum borrowing capacity under certain conditions		$ 2,000,000,000
Outstanding borrowings		$ 0
Subsequent Event | JPMorgan Chase Bank
Debt
Long-term line of credit			$ 1,000,000,000

Debt (Short Term Borriwngs and

Debt (Short Term Borriwngs and Current Portion of Long Term Debt) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Debt
Commercial paper	$ 699.4	$ 99.6
2.450% senior notes due 2015	500.3	506.3
Total, debt	$ 1,199.7	$ 605.9
2.450% senior notes due 2015
Debt
Interest rate (as a percentage)	2.45%

Debt (Senior Notes Carrying Val

Debt (Senior Notes Carrying Values) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Carrying values of the entity's senior notes
Long-term debt	$ 14,297.9	$ 6,265.7
1.900% senior notes due 2017
Carrying values of the entity's senior notes
Long-term debt	$ 503	501
Interest rate (as a percentage)	1.90%
2.125% senior notes due 2018
Carrying values of the entity's senior notes
Long-term debt	$ 999.9	0
Interest rate (as a percentage)	2.125%
2.300% senior notes due 2018
Carrying values of the entity's senior notes
Long-term debt	$ 403.8	401.2
Interest rate (as a percentage)	2.30%
2.250% senior notes due 2019
Carrying values of the entity's senior notes
Long-term debt	$ 511.3	502.5
Interest rate (as a percentage)	2.25%
2.875% senior notes due 2020
Carrying values of the entity's senior notes
Long-term debt	$ 1,497.4	0
Interest rate (as a percentage)	2.875%
3.950% senior notes due 2020
Carrying values of the entity's senior notes
Long-term debt	$ 514.6	502.8
Interest rate (as a percentage)	3.95%
3.250% senior notes due 2022
Carrying values of the entity's senior notes
Long-term debt	$ 1,032.3	1,010.2
Interest rate (as a percentage)	3.25%
3.550% senior notes due 2022
Carrying values of the entity's senior notes
Long-term debt	$ 997.3	0
Interest rate (as a percentage)	3.55%
4.000% senior notes due 2023
Carrying values of the entity's senior notes
Long-term debt	$ 722.2	708.5
Interest rate (as a percentage)	4.00%
3.625% senior notes due 2024
Carrying values of the entity's senior notes
Long-term debt	$ 1,003.4	996.8
Interest rate (as a percentage)	3.625%
3.875% senior notes due 2025
Carrying values of the entity's senior notes
Long-term debt	$ 2,476.1	0
Interest rate (as a percentage)	3.875%
5.700% senior notes due 2040
Carrying values of the entity's senior notes
Long-term debt	$ 249.6	249.5
Interest rate (as a percentage)	5.70%
5.250% senior notes due 2043
Carrying values of the entity's senior notes
Long-term debt	$ 396.7	396.7
Interest rate (as a percentage)	5.25%
4.625% senior notes due 2044
Carrying values of the entity's senior notes
Long-term debt	$ 996.5	996.5
Interest rate (as a percentage)	4.625%
5.000% senior notes due 2045
Carrying values of the entity's senior notes
Long-term debt	$ 1,993.8	$ 0
Interest rate (as a percentage)	5.00%

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shareholder, weighting	25.00%
Performance based, restricted stock unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenue, weighting	37.50%
Earnings per share, weighting	37.50%
Weighted average fair value of PSUs	$ 122.90
Minimum | Performance based, restricted stock unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares issued	0.00%
Maximum | Performance based, restricted stock unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares issued	200.00%

Share-Based Compensation (Compo

Share-Based Compensation (Components of Share-Based Compensation Expense) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 149.9	$ 111.4	$ 426.4	$ 319.2
Tax benefit related to share-based compensation expense	42.8	31.4	124	92.4
Reduction in income	107.1	80	302.4	226.8
Cost of goods sold (excluding amortization of acquired intangible assets)
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	8.5	6.8	23.3	18.8
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	65.2	48.4	185	141.2
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 76.2	$ 56.2	$ 218.1	$ 159.2

Share-Based Compensation (Summa

Share-Based Compensation (Summary of Stock Options, RSUs and PSUs) (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2015shares
Stock Options
Stock option activity
Outstanding at the beginning of the period (in shares)	77,200
Granted (in shares)	8,700
Exercised/released (in shares)	(9,000)
Forfeited (in shares)	(1,300)
Outstanding at the end of the period (in shares)	75,600
Restricted Stock Units
Restricted and Performance-Based Restricted Stock Units
Nonvested at the beginning of the period, share equivalent	9,400
Granted, share equivalent	1,800
Exercised, share equivalent	(3,000)
Forfeited, share equivalent	(300)
Nonvested at the end of the period, share equivalent	7,900
Performance- Based Restricted Stock Units (in thousands)
Restricted and Performance-Based Restricted Stock Units
Nonvested at the beginning of the period, share equivalent	133
Granted, share equivalent	211
Exercised, share equivalent	0
Forfeited, share equivalent	(7)
Nonvested at the end of the period, share equivalent	337

Share-Based Compensation (Unves

Share-Based Compensation (Unvested Awards and Weighted-Average Periods) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 613.4
Expected weighted-average period in years of compensation cost to be recognized	2 years
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 304.3
Expected weighted-average period in years of compensation cost to be recognized	1 year 3 months
Performance- Based Restricted Stock Units (in thousands)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 20.4
Expected weighted-average period in years of compensation cost to be recognized	1 year 8 months 12 days

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits, increase	$ 49.8
Increases to the amount of unrecognized tax benefits	42.2
Accrued interest on unrecognized tax benefits	$ 7.6

Collaboration Agreements (Narra

Collaboration Agreements (Narrative) (Details) shares in Millions

Mar. 26, 2015USD ($)

Mar. 21, 2014USD ($)Collaborative_Arrangement

Mar. 21, 2014

Sep. 30, 2015USD ($)

Jul. 31, 2015USD ($)option_target

Jun. 30, 2015USD ($)shares

Apr. 30, 2015USD ($)

Feb. 28, 2015USD ($)

Dec. 31, 2014USD ($)

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

bluebird

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$ 9,000,000

$ 0

Milestone payments made

0

0

Payment to terminate a collaboration agreement

0

0

bluebird | Discovery and Development Collaboration and License Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestones payment

$ 20,000,000

120,000,000

bluebird | AG-881

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestones payment

$ 70,000,000

Milestone payment, payable

10,000,000

bluebird | AG-881 | Research and Development Collaboration Expense

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

9,000,000

Epizyme

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$ 0

$ 0

0

0

Milestone payments made

0

0

0

0

Payment to terminate a collaboration agreement

10,000,000

0

10,000,000

0

License payments FORMA

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestones payment

$ 430,000,000

FORMA

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Collaboration agreement, term

3 years 6 months

Research and development period

4 years

Upfront Fees

$ 39,000,000

225,000,000

Milestone payments made

0

0

Payment to terminate a collaboration agreement

0

0

FORMA | Research and development payments

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestones payment

200,000,000

FORMA | Regulatory approval

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Potential milestones payment

315,000,000

FORMA | First Collaboration Agreement, First Ex-US License

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$ 19,000,000

FORMA | Second Collaboration Agreement

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$ 225,000,000

Term of additional agreement

2 years

Payment to exercise additional agreements

$ 375,000,000

FORMA | Second Collaboration Agreement | Maximum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of additional agreement | Collaborative_Arrangement

2

FORMA | Second Collaboration Agreement, First Ex-US License

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

20,000,000

MorphoSys

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

0

0

Milestone payments made

0

0

Payment to terminate a collaboration agreement

$ 8,100,000

8,100,000

0

Other Collaboration Arrangements

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

26,900,000

6,000,000

47,900,000

54,000,000

Milestone payments made

0

6,800,000

8,000,000

7,300,000

Payment to terminate a collaboration agreement

$ 0

$ 0

0

0

Acceleron

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

0

0

Milestone payments made

0

0

Payment to terminate a collaboration agreement

0

0

NantBioScience

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

0

50,000,000

Milestone payments made

0

0

Payment to terminate a collaboration agreement

0

0

NantBioScience | Selling, general and administrative

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$ 25,000,000

Collaboration and License Agreement | Epizyme | HMT Inhibitor Targeting Option Targets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 10,000,000

Option targets | option_target

3

Exclusive licenses | option_target

2

Development milestone payment

$ 75,000,000

Regulatory milestone payment

365,000,000

Sales milestone payment

170,000,000

Collaboration and License Agreement | Epizyme | DOT1L Program

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Regulatory milestone payment

100,000,000

Additional development milestone payments

$ 35,000,000

Collaboration and License Agreement | Epizyme | Molecule HMT Inhibitor Targeting DOT1L

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Research and development period

3 years

Termination agreement, period

120 days

Collaboration Agreement | Epizyme | B-Cell Maturation Antigen (BCMA)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contingent consideration

$ 230,000,000

Milestone payment, payable

$ 25,000,000

Termination agreement, period

90 days

Co-development agreement

0.50

Collaboration Agreement | Nurix, Inc | Immune Modulator Assets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 149,800,000

Research and Development Arrangement, Contract to Perform for Others, Equity Investment

$ 17,000,000

Research and development arrangement, contract to perform for others, equity interest

13

Research and development arrangement contract to perform for others, period after delivery of phase I data package

45 days

Research and development arrangement, contract to perform for others, future success-based milestone payments

$ 405,000,000

Research and development arrangement, contract to perform for others, agreement term

4 years

Strategic Collaboration Agreement | MedImmune Limited | MEDI4736

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 450,000,000

Termination agreement, period

9 years

Research and development arrangement, contract to perform for others, cost sharing percentage, period two

7500.00%

Research and development arrangement, contract to perform for others, royalty rate, percentage of worldwide sales

7000.00%

Research and development arrangement, contract to perform for others, final royalty rate

5000.00%

Research and development arrangement, contract to perform for others, royalty rate, period to reach final rate

4 years

Collaboration and Option Agreement | Sutro | Immune Modulator Assets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 82,500,000

Research and development arrangement, contract to perform for others, future success-based milestone payments

$ 190,000,000

Termination agreement, period

6 months

Research and development arrangement, contract to perform for others, agreement term

3 years

Collaboration and Option Agreement | Sutro | Immune Modulator Assets | Research and Development Collaboration Expense

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 69,500,000

Collaboration and Option Agreement | Acetylon | Attainment of Developmental, Regulatory and Sales Milestones [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Research and development arrangement, contract to perform for others, future success-based milestone payments

$ 120,000,000

Collaboration and Investment Agreement | Juno Therapeutics, Inc | Development and Commercialization of Immuno-Therapeutics

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

150,000,000

Research and development arrangement, contract to perform for others, premium paid on equity investment

$ 425,100,000

Termination agreement, period

120 days

Research and development arrangement, contract to perform for others, agreement term

10 years

Research and development arrangement, contract to perform for others, cost and profit sharing percentage, agreement owner

70

Research and development arrangement, contract to perform for others, cost and profit sharing percentage, counterparty

30

Research and development arrangement, investment in counterparty, consideration to be transferred

$ 1,000,000,000

Research and development arrangement, contract to perform for others, shares of counterparty common stock | shares

9.1

Research and development arrangement, contract to perform for others, percentage of counterparty common stock

0.09

Reserach and Development Arrangement Investment in Counterparty, Value of Shares

$ 424,900,000

Manufacturing Rights Asset | bluebird | AG-881

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 1,000,000

Noncurrent Assets | Collaboration and Option Agreement | Sutro | Immune Modulator Assets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

13,000,000

Equity Investment Asset | Collaboration and Option Agreement | Sutro | Immune Modulator Assets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

10,000,000

Option to license | Collaboration and Option Agreement | Sutro | Immune Modulator Assets

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Milestone payment, payable

$ 3,000,000

Collaboration Agreements (Perio

Collaboration Agreements (Period Activity) (Details) - USD ($) $ in Millions	Mar. 26, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Acceleron
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				$ 0	$ 0
Milestones				0	0
Extension/Termination of Agreements				0	0
Amortization of Prepaid R&D and Intangibles				0	0
Equity Investments Made During Period				0	52.4
Acetylon
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		$ 0	$ 0	0	0
Milestones		0	0	0	0
Extension/Termination of Agreements		0	0	0	0
Amortization of Prepaid R&D and Intangibles		5.4	4.3	14.6	11.4
Equity Investments Made During Period		0	0	0	0
bluebird
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				9	0
Milestones				0	0
Extension/Termination of Agreements				0	0
Amortization of Prepaid R&D and Intangibles				0	0
Equity Investments Made During Period				0	13
AstraZeneca
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				450
Milestones				0
Extension/Termination of Agreements				0
Amortization of Prepaid R&D and Intangibles				0
Equity Investments Made During Period				0
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		0	0	0	0
Milestones		0	0	0	0
Extension/Termination of Agreements		0	0	0	0
Amortization of Prepaid R&D and Intangibles		2.1	0.1	0.1	2.8
Equity Investments Made During Period		0	0	0	0
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		0	0	0	0
Milestones		0	0	0	0
Extension/Termination of Agreements		10	0	10	0
Amortization of Prepaid R&D and Intangibles		0	0	0	0
Equity Investments Made During Period		0	0	0	9.9
Juno Therapeutics, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		575.1		575.1
Milestones		0		0
Extension/Termination of Agreements		0		0
Amortization of Prepaid R&D and Intangibles		0		0
Equity Investments Made During Period		424.9		424.9
Nurix, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees			149.8	149.8
Milestones			0	0
Extension/Termination of Agreements			0	0
Amortization of Prepaid R&D and Intangibles			0	0
Equity Investments Made During Period			17	17
FORMA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				39	225
Milestones				0	0
Extension/Termination of Agreements				0	0
Amortization of Prepaid R&D and Intangibles				0	0.1
Equity Investments Made During Period				0	0
Sutro
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				69.5
Milestones				0
Extension/Termination of Agreements				0
Amortization of Prepaid R&D and Intangibles				0
Equity Investments Made During Period				10
MorphoSys
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				0	0
Milestones				0	0
Extension/Termination of Agreements	$ 8.1			8.1	0
Amortization of Prepaid R&D and Intangibles				0	0
Equity Investments Made During Period				0	0
NantBioScience
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees				0	50
Milestones				0	0
Extension/Termination of Agreements				0	0
Amortization of Prepaid R&D and Intangibles				0	0
Equity Investments Made During Period				0	90
Sutro Biopharma, Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		0	72.6	0	72.6
Milestones		0		0	0
Extension/Termination of Agreements		0		0	0
Amortization of Prepaid R&D and Intangibles		1.4	0.1	3.4	0.2
Equity Investments Made During Period		0	11.9	0	11.9
Other Collaboration Arrangements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront Fees		26.9	6	47.9	54
Milestones		0	6.8	8	7.3
Extension/Termination of Agreements		0	0	0	0
Amortization of Prepaid R&D and Intangibles		0	0.4	0.9	6.9
Equity Investments Made During Period		$ 0	$ 27	$ 50	$ 47.9

Collaboration Agreements (Per71

Collaboration Agreements (Period End Balances) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 10,715.8	$ 4,067.6
Acceleron
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	0	0
Equity Investment Balance	$ 114.8	$ 179.7
Percentage of Outstanding Equity	14.00%	14.00%
Acetylon
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 5.8	$ 20.4
Equity Investment Balance	$ 25	$ 25
Percentage of Outstanding Equity	11.00%	10.00%
bluebird
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 1	$ 0
Equity Investment Balance	$ 370.1	$ 587.4
Percentage of Outstanding Equity	13.00%	14.00%
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 22.3	$ 0.1
Epizyme
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	0	0
Equity Investment Balance	$ 47.3	$ 69.3
Percentage of Outstanding Equity	8.00%	11.00%
FORMA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 0.1	$ 0.1
Juno Therapeutics, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	0
Equity Investment Balance	$ 371.8
Percentage of Outstanding Equity	9.00%
Sutro
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 3
Equity Investment Balance	$ 10
Percentage of Outstanding Equity	8.00%
MorphoSys
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 0	0
Equity Investment Balance	$ 53.1	$ 73.9
Percentage of Outstanding Equity	3.00%	3.00%
NantBioScience
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 0	$ 0
Equity Investment Balance	$ 90	$ 90
Percentage of Outstanding Equity	13.00%	14.00%
Nurix, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 0.2
Equity Investment Balance	$ 17
Percentage of Outstanding Equity	13.00%
Sutro Biopharma, Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 24.4	$ 12.8
Equity Investment Balance	$ 17.6	$ 17.6
Percentage of Outstanding Equity	15.00%	15.00%
Other Collaboration Arrangements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Intangible Asset Balance	$ 22.1	$ 34.4
Equity Investment Balance	$ 130.1	$ 90.8

Legal Proceedings (Narrative) (

Legal Proceedings (Narrative) (Details)	Apr. 11, 2014lawsuit	Apr. 03, 2014Patents	Oct. 02, 2013lawsuit	Jun. 07, 2013	Feb. 28, 2014lawsuitplaintiff	Dec. 31, 2012	Sep. 30, 2015USD ($)	Jul. 31, 2014number_of_stockholders
Loss Contingencies [Line Items]
Domicile of litigation						2
Number of Stockholders | number_of_stockholders								2
Andrulis Pharmaceuticals Corporation Patent Infringement
Loss Contingencies [Line Items]
Claims dismissed	2
Patents allegedly infringed	4		1
Litigation Related to Sales of THALOMID and REVLIMID
Loss Contingencies [Line Items]
Number of civil qui tam actions					3
Number of plaintiffs | plaintiff					3
Children's Medical Center Corporation
Loss Contingencies [Line Items]
Range of possible loss, minimum | $							$ 0
Range of possible loss, maximum | $							$ 126,300,000
Children's Medical Center Corporation | revlimid royalty
Loss Contingencies [Line Items]
Royalty rate				0.01
Children's Medical Center Corporation | pomalyst royalty
Loss Contingencies [Line Items]
Royalty rate				0.025
Pending Litigation | Natco, Arrow and Watson
Loss Contingencies [Line Items]
Patents allegedly infringed | Patents		5

Subsequent Eventt (Narrative) (

Subsequent Eventt (Narrative) (Details) - Summit New Jersey Campus - Subsequent Event ft² in Thousands	1 Months Ended
	Oct. 31, 2015ft²number_of_buildingsnumber_of_campuses
Business Acquisition [Line Items]
Number of buildings | number_of_buildings	12
Number of campuses | number_of_campuses	2
Administrative office space
Business Acquisition [Line Items]
Area of business facilities	850
R&D space
Business Acquisition [Line Items]
Area of business facilities	450
Addition at global headquarters
Business Acquisition [Line Items]
Area of business facilities	550